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Summary 
Both genetic and epigenetic defects causing alterations to gene expression are 
implicated in cancer development. Epigenetic repression of gene transcription through 
DNA methylation is one of the fundamental mechanisms for inactivation of tumor 
suppressor genes in many cancers. Thus, identification of these silencing tumor 
suppressor genes could provide insight into the biological processes and pathways 
underlying tumorigenesis. In this thesis, we provide a comprehensive approach that 
integrates gene expression and ChIP-seq data for identification of DNA methylation 
silencing tumor suppressors and their-associated signaling pathways in colorectal 
cancer. A total of 203 colon cancer methylation silencing (CMS) genes have been 
identified and further characterized. Among the 203 CMS genes, PPP2R2B, one of 
the regulatory B subunits of protein phosphatase 2A (PP2A), was selected for further 
functional study.  
Tumor suppressor PP2A complex is a major serine/threonine phosphatase that 
serves as a critical cellular regulator of cell growth, proliferation, and survival. 
However, how its change in human cancer confers growth advantage is largely 
unknown. This study shows that PPP2R2B, encoding the B55β regulatory subunit of 
PP2A complex, is epigenetically inactivated by DNA hypermethylation in most of 
human colorectal cancer patients. Functional studies show that PPP2R2B 
re-expression in colorectal cancer (CRC) cells resulted in senescence, decreased cell 
proliferation, and xenograft tumor growth inhibition. In addition, PPP2R2B 
knockdown promotes cellular transformation in immortalized human epithelial cells. 
viii 
Therefore, gain- and loss-of-function data suggest that the loss of PPP2R2B facilitates 
oncogenic transformation. Mechanistically, we have demonstrated that PPP2R2B 
forms a functional PP2A complex targeting and inhibiting p70S6K and Myc 
phosphorylation. Taken together, our data show that PPP2R2B-specific PP2A 
complex functions as a tumor suppressor and its loss contributes to the deregulated 
S6K and Myc signaling, leading to growth advantage of CRC.  
Furthermore, we show that PPP2R2B-regulated tumor suppressor pathway has 
a role in modulating mTOR inhibitor sensitivity. The mTOR signaling pathway plays 
a central role in tumor development, making this pathway as attractive target for 
cancer therapy. Small molecule drugs targeting mTOR, such as rapamycin, have 
been shown to be promising for cancer therapy. However, the clinical responses to 
the rapamycin as mTOR-targeted therapy are frequently confounded by acquired 
resistance. In colon cancer, loss of PPP2R2B leads to induction of PDK1-dependent 
Myc phosphorylation in response to rapamycin. Conversely, re-expression of 
PPP2R2B blocks the PDK1-Myc signaling, leading to re-sensitization to rapamycin. 
We also show that genetic ablation or pharmacologic inhibition of PDK1 abrogates 
rapamycin-induced Myc phosphorylation, leading to rapamycin sensitization. Thus, 
our data demonstrate a new mechanism underlying rapamycin resistance in CRC, 
which is independent of PI3K-AKT and MAPK negative feedback loops. Together, 
these results identified PPP2R2B as a new biomarker to predict the rapamycin 
response and also provided a new therapeutic strategy to overcome the rapamycin 
resistance in cancer therapy. 
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1.1 Loss of tumor suppressor genes by genetic and 
epigenetic alterations in cancer  
Cancer is a complex disease in which the phenotypes of different types of 
cancers correlate with distinct genetic and epigenetic alterations. A wide range of 
genetic alterations, including somatic point mutations, deletions, chromosomal 
rearrangements and copy number changes, lead to inactivation of tumor suppressor 
and activation of oncogenes during cancer development. In addition to the widely 
observed genetic changes, epigenetic alterations are also found to play a important 
role in tumor progression. Gene suppression by epigenetic alteration is commonly 
mediated through DNA methylation and histone modification. In this section, I will 
briefly discuss the role of genetic and epigenetic changes leading to inactivation of 
tumor suppressor genes in tumor progression.  
1.1.1 Genetic alterations as a cause of loss-of-function of tumor 
suppressor genes in cancer  
Cancer is essentially a genetic disease arising from the concerted effect of 
multiple genetic changes that result in the dysregulation of cellular signaling 
pathways (2011; Jones et al., 2008). To date, large-scale cancer genomics 
experiments by next-generation DNA sequencing technologies have detected 
molecular alterations across a wide range of human cancers (Beroukhim et al., 2010; 
Kan et al., 2010; Wood et al., 2007). A catalogue of genomic abnormalities that drive 
cancer progress is essential for the development of novel therapeutics. Furthermore, 
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genomic alterations as biomarkers to guide patient selection for clinical trials are 
crucial to the success of development of new treatment.  
A tumor suppressor gene is a gene that protects cells from becoming cancerous. 
The most established tumor suppressors include p53, Rb, APC, PTEN, and FBW7, 
which are frequently inactivated by somatic mutations and genetic deletions in 
different human malignancies (Li et al., 1997; Su et al., 1993; Welcker and Clurman, 
2008). Inactivation of these tumor suppressor genes results in constitutive 
hyperactivation of various oncogenic signaling pathways, leading to uncontrol cell 
proliferation and tumorigenecity. For instance, Inactivating mutations in APC gene, 
which encodes the tumor suppressor adenomatosis polyposis coli (APC), leads to the 
activation of the WNT pathway and are often found in colorectal cancer cells 
(Kinzler and Vogelstein, 1997; Weinstein, 2002). Restoration of APC function blocks 
activation of the WNT signaling pathway through phosphorylation and degradation 
of β-catenin. PTEN (phosphatase and tensin homolog) is one of the most commonly 
silenced tumor suppressors in many human cancers, such as glioblastoma, prostate, 
and breast cancer (Li et al., 1997). Loss of functional PTEN in cancer cells leads to 
constitutive activation of the PI3K pathway which include the AKT and mTOR 
kinases.  
A wide range of methodologies were adopted for identification of tumor 
suppressor. Traditional genetic and cellular methodologies allow us to uncover a 
number of tumor suppressor and their functions. For example, gain-of and 
loss-of-function analyses for these tumor suppressor genes are necessary to validate 
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the function of such genes as tumor suppressors during cancer development. 
Moreover, recent development of technologies for whole-genome sequencing, copy 
number analysis and expression profiling enables the generation of comprehensive 
molecular descriptions of tumor suppressor genes, which allow the identification of 
new oncogenic signaling that are dysregulated by inactivation of these tumor 
suppressor genes in the malignancy (Berger et al., 2011; Beroukhim et al., 2010; Kan 
et al., 2010; Stratton et al., 2009).  
1.1.2 Aberrant DNA methylation as a cause of tumor suppressor 
genes silencing in cancer  
Epigenetic regulation is a heritable gene expression changes that occurs 
without alteration in genomic DNA sequence. DNA methylation involves addition of 
a methyl group to the 5’ position of cytosines within CpG dinucleotides, which is 
mainly mediated by DNA methyltransferases (DNMTs) such as DNMT1, DNMT3a 
and DNMT3b (Rhee et al., 2002). DNA hypermethylation has been well-established 
to be a crucial mechanism that results in silencing of tumor suppressor genes 
(Herman and Baylin, 2003). For instance, the DNA hypermethylation of CDKN2A 
(cyclin-dependent kinase inhibitor 2A) (Herman et al., 1995; Merlo et al., 1995), 
hMLH1 (mutL homologue-1), and BRCA1 (breast-cancer susceptibility gene 1) 
(Esteller, 2000; Herman and Baylin, 2003) have led to their loss of expression in 
many solid tumors (Baylin et al., 2000). More recently, epigenetic inactivation of 
WNT antagonists such as secreted frizzled-related gene family (SFRPs) and 
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Dickkopf3 (DKK3) activates the Wnt/β-catenin pathway, thereby promoting the 
growth of cancer cells (Baylin and Ohm, 2006; Suzuki et al., 2004; Yue et al., 2008). 
Studies have shown that the genome wide profiles of DNA methylation of tumor 
suppressor genes are specific to the cancer type (Esteller et al., 2001). Thus, 
genome-wide profiling epigentic alterations of tumor suppressor genes and their 
related signaling pathways will provide the new understanding the biological 
processes underlying .   
1.2  The role of tumor suppressor PP2A in cancer development 
The serine/threonine protein phosphatase type 2A (PP2A) is a trimeric 
holoenzyme that serves as a critical cellular regulator of cell growth, proliferation, 
and survival (Westermarck and Hahn, 2008). Increasing evidences indicate that 
PP2A works as a tumor suppressor in human cancer. However, the molecular 
mechanisms by which PP2A activity is inactivated in human cancer is largely 
unknown. In this section, I will discuss the structure and regulation of PP2A 
complex. More importantly, I will focus on the regulatory mechanisms of PP2A 
involved in cellular transformation and discuss the current findings in the molecular 
mechanisms of PP2A disruption in human malignancies. 
1.2.1 PP2A structure  
PP2A belongs to the phosphoprotein phosphatase (PPP) family of Ser/Thr 
phophatases and functions as a trimeric holoenzyme consisting of a catalytic subunit 
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(PP2A C), a scaffolding A-subunit and one of a large array of regulatory B-subunits 
(Janssens and Goris, 2001). In mammalian cells, PP2A C subunit is constitutively 
bound to the structural subunit (PP2A A) to form the core of the enzyme. Variable 
regulatory B subunits (PP2A B) that associate with the core enzyme determine the 
specificity of its substrates. PP2A catalytic activity is encoded by two distinct Cα 
and Cβ subunits (Stone et al., 1987). The catalytic C subunit has a highly conserved 
domain at the C-terminal tail, which determines the interaction of A subunit and 
recruitment of B subunit (Longin et al., 2007). Two alternative genes, PPP2R1A (Aα) 
and PPP2R1B (Aβ), encode the two distinct structural subunits, which differ in their 
ability to interact with the various regulatory B subunits (Groves et al., 1999). The A 
subunits primarily serve a structural role and maintain the PP2A holoenzyme 
composition (Ruediger et al., 1999). The regulatory B subunits have been further 
divided into four distinct families as shown in the Figure 1.1 and each family 
consists of several members: B (B55 or PR55), B′ (B56 or PR61), B′′ (PR48, PR72, 
and PR130) and B′′′ (PR93/ PR110). Each of the B subunit binds to the A subunit 
mutual exclusively. More than 200 biochemically distinct PP2A complexes were 
discovered from differential combinations of A, B, and other subunits. The diversity 
of PP2A heterotrimers suggests that particular regulatory subunits mediate 
specificphysiological functions through regulating specific substrates in different 
mammalian tissues (Virshup and Shenolikar, 2009). However, the roles of specific 
PP2A complexes in the cellular functions remain elusive.  
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Figure 1.1 The structure of PP2A complex 
PP2APP2A is a heterotrimeric complex composed of a structural A subunit, a catalytic 
C subunit (pink) and one of several B regulatory subunits (yellow, orange, red and 
blue). B subunits regulate the activity and localization of PP2A complexes. Several 
forms of each of these subunits exist in humans, and thus many different enzymatic 
complexes can be formed. (Westermarck and Hahn, 2008) 
 
1.2.2 The regulation of PP2A activity       
PP2A has serine/threonine protein phosphatase activity that functions to 
dephosphorylate various kinases that are involved in many different signaling 
pathways. Virus infection and somatic mutations can cause the disruption of PP2A 
complex and loss of functions in cellular process. For example, inactivating 
mutations of structural A subunit disrupt the ability of scaffolding to form an active 
PP2A complex with specific regulatory subunits, leading to cellular transformation 
(Arroyo and Hahn, 2005).  
In addition, the activity of PP2A could also be regulated by a number of other 
8 
cellular and viral proteins. For instance, the SV40 small T antigen alters PP2A 
activity by displacing the regulatory B subunit from the holoenzyme complexes 
(Pallas et al., 1990). Recent studies indicated that phosphorylation and methylation 
of the C-terminal tail of the catalytic PP2A subunit (PP2A C) play an important role 
in the regulation of both catalytic activity of PP2A C and recruitment of different B 
subunits to the PP2A complex. PP2A structural study indicated that PP2A is 
regulated through the post-translational modification such as methylation by a 
methylating enzyme, LCMT, and methyl esterase PME-1 (Xing et al., 2008). 
Generally, the cellular activity of PP2A complex is dependent on the binding partner 
of its core dimer and post translational modification, resulting in the control of 
various cellular processes, including cell growth, adhesion, and cytoskeletal 
dynamics. In particular, recent studies have elucidated roles for PP2A in cell 
transformation and tumorigenesis (Junttila et al., 2007; Sablina et al., 2007).  
1.2.3 PP2A functions in transformation models 
PP2A plays an integral role in the regulation of a number of major signaling 
pathways, including cell proliferation, survival and cell transformation. However, the 
activity of PP2A in many cellular processes has been an impediment to defining its 
role as a tumor suppressor. Genetic manipulation of the catalytic C or scaffolding A 
subunits affects the phosphorylation of hundreds of proteins in many cellular 
processes, which make it difficult to dissect the functions of PP2A in cellular 
transformation and other cellular processes.  
9 
PP2A was first suggested to act as tumor suppressor based on the okadaic acid  
as selective inhibitor of PP2A (Suganuma et al., 1988). OA was shown to inhibit 
PP2A activity and potently promoted tumors in a mouse model of carcinogenesis, 
which was later demonstrated to be caused by the activation of several oncogenic 
signaling pathways. The second evidence came from the discovery that PP2A was 
the target of several tumor-promoting viruses such as simian virus SV40 and 
polyoma virus (Andrabi et al., 2007; Hahn et al., 2002). Interestingly, the alteration 
of PP2A by viral proteins leads to the deregulation of similar pathways which were 
found to be disturbed by okadaic acid. For instance, ST specifically replaced B56γ to 
disrupt the PP2A complex and inhibit its activity in this ST-dependent transformation 
model.  
Several reports have proposed the underlying molecular mechanisms of 
cellular transformation driven by altered PP2A function. Recent studies indicate that  
pyST appears to preferentially activate the MAP kinase pathway while ST stimulates 
AKT phosphorylation in a PP2A-dependent manner (Andrabi et al., 2007; Chen et 
al., 2005). By using this transformation model dependent on the tumor-promoting 
viral antigen, several groups have identified pathways and proteins that are involved 
in the tumor suppressor functions of PP2A. For example, Myc was previously 
identified as a direct target of PP2A regulation (Arnold and Sears, 2006). PP2A 
holoenzyme containng the B56α dephosphorylates Myc at Serine 62 targeting Myc 
degradation. Conversely, inactivation of PP2A by ablation of B56 or ectopic 
expression of ST results in Myc stabilization and contributes to cellular 
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transformation (Arnold et al., 2009; Yeh et al., 2004). Moreover, by using a 
comprehensive loss-of-function approach, Sablina showed that manipulation of 4 
distinct PP2A complexes results in human cell transformation through activation of 
c-Myc, Wnt, and PI3K oncogenic pathways (Sablina et al., 2010). Taken together, 
these studies systematically identify the specific PP2A complexes involved in 
control of cell transformation and define the PP2A-dependent pathways involved in 
cellular transformation. However, more studies are necessary to provide a more 
complete view of the molecular mechanisms by which specific PP2A complexes 
affect these oncogenic pathways in human malignancies.  
1.2.4 Mechanisms and cellular consequence of PP2A disruption in 
human cancer 
PP2A complexes regulate a variety of signaling pathways involved in cellular 
transformation. However, the precise role of PP2A deregulation during tumor 
progression is not clear and the mechanism by which PP2A dysfunction induces 
tumorigenesis remains elusive. Furthermore, it is also possible that different set of 
genetic and/or epigenetic alterations during tumor formation require the loss of 
different PP2A complexes for the tumor to survive. As such, the role of PP2A as a 
tumor suppressor is likely to be more diverse than initially suggested and to be 
largely context-dependent. While the evidence exists implicating that PP2A 
complexes play important roles in human cell transformation, investigation of a 
direct relevance to human cancer has been so far limited. The majority of the work 
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has involved screening tumor samples and cell lines for somatic mutations in PP2A 
subunit genes. For example, somatic mutations in the PP2A A subunits have been 
reported in human lung, breast and colon cancers, although at low frequency (Wang 
et al., 1998). Biochemical studies confirmed that PP2A A subunits mutations disrupt 
the ability of such mutants to form PP2A complexes and the cancer–associated PP2A 
A subunits mutants are functionally defective in binding to specific B subunits and in 
phosphatase activity. For instance, PP2A complex containing B56γ subunit regulates 
the phosphorylation of AKT and cancer-associated A subunit mutations lead to 
haploinsufficiency, loss of Aα complexes containing B56 and eventually increased 
phosphorylation of AKT and tumor formation (Chen et al., 2005). In contrast, 
cancer-associated PP2A Aβ subunit mutations lead to the complete loss of function 
of PP2A complexes and increased RalA GTPase phosphorylation (Andrabi et al., 
2007; Sablina et al., 2007). These findings suggest that loss or alteration of PP2A 
activity by cancer-associated mutations is an essential step in tumor development 
and supports the notion that PP2A acts as a tumor suppressor in human malignancies. 
Although these observations suggest that cancer-associated PP2A A subunits mutants 
contribute to human cell transformation, the low frequency of mutation in PP2A 
subunits limit the wider implication of PP2A as a tumor suppressor in many human 
cancers.  
In addition to the PP2A structural A subunits’ somatic mutations, aberrant 
expression of PP2A subunits are observed in human cancers. For example, PP2A 
B56γ deletion was found in lung cancer and reactivation of B56γ inhibits cancer cell 
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growth in vitro and in vivo (Chen et al., 2004). Another link between PP2A 
complexes and tumorigenesis is found in the Wnt signaling pathway, which play 
important role in cancer development. The adnomatous polyposis coli (APC), axin 
and glycogen synthase 3β form a Wnt regulated signaling complex that mediates the 
phosphorylation-dependent degradation of β-catenin. PP2A holoenzyme forms a 
specific complex with APC through its regulatory B56α subunit. Overexpression of 
this subunit causes proteasomal degradation of β-catenin and thereby inhibits Wnt 
signaling in human cancer (Morin et al., 1997; Seeling et al., 1999).  
In contrast to genetic inactivations of PP2A subunits, overexpression of 
endogenous PP2A inhibitor proteins, such as SET and CIP2A, might also inhibit 
PP2A tumor suppressor activity (Junttila et al., 2007; Neviani et al., 2005). Recent 
work has identified that SET was overepressed in chronic myelogenous leukemia 
(CML) and its expression was correlated with the oncogenic activity of BCR-ABL 
kinase. Moreover, the phosphatase activity of the tumor suppressor PP2A is inhibited 
by the BCR-ABL-induced expression of SET. Specifically, reactivation of PP2A by 
ablation of SET or by pharmacological inhibition of BCR-ABL led to Myc 
degradation and also inhibition of other PP2A targets. Consequently, these 
observations indicate that functional inactivation of PP2A might be essential for 
BCR-ABL leukemogenesis and also required for blastic transformation. CIP2A 
(cancerous inhibitor of PP2A) was previously identified as PP2A inhibitor protein by 
using a proteomic approach. It was shown that CIP2A can stabilize Myc protein by 
inhibiting the catalytic activity of the PP2A towards Myc S62 phosphorylation. In 
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contrast, further functional studies indicated that CIP2A is overexpressed in two 
human malignancies including head and neck squamous cell carcinomas (HNSCCs) 
and colon cancers. Importantly, ectopic expression of CIP2A can also replace ST to 
promote cell transformation. Consistent with a role of CIP2A in transformation, 
knockdown of CIP2A by short interference RNA (siRNA) in squamous cell 
carcinoma cell lines expression high levels of CIP2A markedly blocks the tumor 
formation through inhibition of Myc.   
In summary, the studies discussed above have established that PP2A is a bona 
fide tumor suppressor protein. A variety of mechanisms for inhibiting PP2A are 
present in transformed cells and disruption of PP2A complexes is a common feature 
in human malignancy. However, as the majority of evidence supporting the role of 
PP2A as tumor suppressor has been obtained by using viral antigens or chemical 
inhibitors, the in vivo mechanisms by which PP2A activity is inhibited remains 
elusive in different cancer types. Moreover, further studies are necessary to identify 
alterations in PP2A and/or its inhibitor proteins, as these alterations might serve as 
biomarkers for cancer diagnostic and targeted therapies. Taken together, unraveling 
the mechanisms of PP2A signaling in human cancer may provide new insights into 
cancer development and identify novel targets for cancer therapy. 
1.3 The mTOR pathway and cancer 
The phosphatidylinositide 3-kinase (PI3K) pathway is most commonly 
activated in a wide range of human cancers in regulating cell growth, proliferation, 
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and metabolism (Engelman et al., 2006; Wong et al., 2010). Different genetic and 
epigenetic alterations were reported for the aberrant activation of this pathway. First, 
activating mutations of PI3K upstream activators such as RAS or receptor tyrosine 
kinases (RTKs), enhance PI3K activity in many cancer types (She et al., 2008). 
Secondly, this pathway is also activated by activating mutations of PIK3CA or 
inactivation of PTEN (Li et al., 1997; Samuels et al., 2004). In this section of review, 
I will briefly introduce the mTOR pathway and its cellular functions. More 
importantly, I will highlight the recent progress of the aberrant activations of mTOR 
signaling in human cancer and the contribution of mTOR to cancer development. 
1.3.1 Overview of PI3K/AKT/mTOR signaling pathway 
The components of the PI3K pathway include upstream activators of PI3K 
enzyme (such as RTKs and Ras), PI3K catalytic subunit p110 and regulatory subunit 
p85, PTEN, downstream effectors (such as PDK1, AKT and mTOR) and 
transcription factors (such as c-Myc and IKK). Figure 1.2 shows a simplified 
overview of the PI3K-AKT-mTOR pathway. Briefly, PI3K are activated by 
cell-surface receptors, such as receptor tyrosine kinases (RTKs), G protein-couple 
receptors (GPCRs), and RAS. and subsequently catalyzes the conversion of PIP2 to 
PIP3. Conversely, phosphatase and tensin homolog (PTEN) is a tumor suppressor 
that antagonizes PI3K activity by converting PIP3 to PIP2. PIP3 initiates the 
activation of AKT to activate multiple downstream effectors, including mTOR, 
forkhead transcription factor (FOXO), glycogen synthnase kinase-3 (GSK3), and 
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BCL2-associated agonist of cell death, which regulate multiple cellular processes, 
such as metabolism, proliferation, and survival. Among these downstream effectors, 
mTOR signaling is extensively studied as it is hyperactivated in human malignancies 
and drugs targeting its activity are now in clinical use.   
 
Figure 1.2 A simplified overview of the PI3K-AKT-mTOR pathway 
GPCR, G protein-coupled receptor; RTK, receptor tyrosine kinase; mTOR mammalian target of 
rapamycin; mTORC1, mTOR complex 1; PI3K, phosphatidylinositol 3-kinase; PIP3, 
phosphatidylinositol-3,4,5-triphosphate; PIP2, phosphatidylinositol-3,4,5-diphosphate; PTEN, 
phosphatase and tensin homolog. 
1.3.2 mTOR signaling components and cellular function 
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that has 
been identified as a critical downstream effector of PI3K/AKT signaling pathway. 
mTOR signaling regulates a series of cellular functions including cell growth by 
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controlling mRNA translation, ribosome biogenesis, autophagy, and metabolism 
through its downstream effectors such as S6 kinase (S6K) and 4EBP1 (Guertin and 
Sabatini, 2005; Sarbassov et al., 2005). mTOR exists in two distinct intracellular 
complexes called mTOR complex1(mTORC1) and mTOR complex2 (mTORC2). As 
shown in the figure 1.3, Both mTORC1 and mTORC2 complexes comprise of the 
mTOR catalytic subunit with different regulatory-associated proteins of mTOR, such 
as Raptor (mTORC1) and Rictor (mTORC2) (Guertin and Sabatini, 2007; Hay and 
Sonenberg, 2004; Sancak et al., 2007). The mTORC1 complex is sensitive to 
rapamycin and its analogs; conversely, mTORC2 is a rapamycin-insensitive complex 
(Sarbassov et al., 2004).  
 
Figure 1.3 The mTORC1 and mTORC2 complexes 
As shown in the Figure 1.4, mTORC1 is activated by AKT through a pathway 
that involves the tuberous sclerosis complex (TSC1-TSC2) as well as the small G 
protein Ras homolog enriched in brain (Rheb). Activated mTORC1 phosphorylates 
translational regulator S6K1 and the eukaryotic translation initiation factor 4E 
(eIF-4E) binding proteins (4E-BP1 and 4E-BP2), which are the only extensively 
described mTORC1 substrates (Sarbassov et al., 2006). Activated S6K 
phosphorylates the ribosomal protein S6, controlling the rate of translation and 
promoting cell growth; while activated 4E-BP1 release the initiation factor elF4E, 
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allowing the initiation of translation (Gingras et al., 2004). S6K also works as a key 
upstream effector of mTORC1, activated S6K inhibits the insulin receptor substrate 
1(IRS1), suppressing IRS1-mediated activation of the PI3K pathway, which leads to 
a negative feedback that downregulates PI3K signaling (Sarbassov et al., 2005). In 
contrast, mTORC2 activates AKT (at serine 473) and SGK1 and is part of the PI3K 
pathway. mTORC2-induced phosphorylation of S473 in the C-terminal hydrophobic 
motif is necessary for the full activation of AKT (Alessi et al., 1996). Furthermore, 
ablation of the mTORC2 components mTOR or rictor, but not raptor by 
loss-of-function RNAi experiments leads to a complete loss of AKT S473 
phosphorylation in a variety of mammalian cells (Sarbassov et al., 2006; Sarbassov 
et al., 2005). Taken together, these findings suggest that mTORC2 directly activates 







Figure 1.4 The mTOR signaling pathway. 
The functional mTOR signaling complex exists in two forms: mTORC1 and mTORC2. Growth 
factor stimulation signals through PI3K to activate AKT leading to mTORC1 activation. 
mTORC2 may also activate AKT via phosphorylation of Ser473. Two major substrates of 
mTORC1 are 4E-BP1 and S6K, whose phosphorylation promotes the translation of key cell 
cycle regulators and transcription factors. 
  
mTOR plays a key role in the regulation of cell proliferation, angiogenesis, 
autophagy, and cell metabolism. For instance, mTOR regulates cell proliferation by 
promoting the translation of cyclinD1 and c-Myc (Nelsen et al., 2003). Furthermore, 
activated mTOR may also play an additional role in cell cycle progression through 
the regulation on the production of p21, the regulatory protein that stops the cell 
cycles in cell proliferation (Beuvink et al., 2005). Thus, inhibition of mTOR leads to 
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cell cycle arrest or growth inhibition. In addition, mTOR activation also promotes 
angiogenesis through control the protein synthesis of hypoxia inducible factor 1α/β 
(HIF1α/β), which are subunits of a master transcription factor that mediates the 
expression of genes that produce angiogenic factors (Pouyssegur et al., 2006; 
Semenza, 2003). Since mTOR activity is also controlled by the cellular environment, 
it is also a critical inhibitor of autophagy (Crazzolara et al., 2009). Recently 
bioenergetics research has shown that mTOR plays a key role in regulating cell 
metabolism (Wullschleger et al., 2006).  
1.3.3 Deregulation of mTOR hyperactivity in cancer   
Although genetic alterations of mTOR have not been reported in human 
cancers, numorous reports indicate that deregulation of upstream pathway effectors 
can lead to hyperactivation of the mTOR signaling. For example, loss or inactivating 
mutations of tumor suppressors such as PTEN and TSC1/2 promote PI3K-dependent 
activation of mTOR (Sabatini, 2006). 
In addition to the alterations of the upstream effectors, genetic amplification of 
its downstream effectors such as elF4E, S6K1 and 4E-BP1, result in enhanced 
mTOR activation, which contributes to its hyperactivity in human cancer. For 
instance, amplification of elF4E has been linked to a wide range of human cancer, 
which also mediates oncogenic transformation (Kentsis et al., 2004). Moreover, the 
overexpression of S6K and downregulation of 4E-BP1 were reported in breast, 
ovarian, and other cancers (Dowling et al., 2009). Notably, a recent report showed 
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that active S6K directly phosphorylates the tumor suppressor PDCD4 (programmed 
cell death protein 4), targeting it for degradation and leading to cancer (Dorrello et 
al., 2006). However, S6K is also involved in the negative feedback inhibition of AKT, 
its contribution towards tumorigenesis might be limited. Thus, identification of new 
mTOR substrates will be important to understand the mechanisms by how mTOR 
signaling deregulated in human cancer.  
Recent studies showed that silencing of targets of mTORC1 with tumor 
suppressive function are also involved in the aberrant of mTOR signaling during 
cancer development. For example, Grb10 (growth factor receptor-bound protein 10) 
was recently identified as mTORC1 substrate, was found to be frequently 
downregulated in various cancers. Experimental results showed that mTORC1 
phosphorylates and promotes Grb10 stabilization, resulting in feedback inhibition of 
the PI3K and ERK-MAPK pathway (Hsu et al., 2011; Yu et al., 2011). Taken 
together, these findings link aberrant activation mTOR signaling to genetic 
alterations in cancer. As a result, mTOR has emerged as an important target for 
anti-cancer therapy.  
In summary, this part of the review collectively shows the various components 
and cellular functions of mTOR pathway. In cancer cells, genetic alterations of key 
components in the PI3K pathway result in a constitutive activation of mTOR 
signaling, which make these components attractive targets for cancer therapy, such 
as small molecules inhibitors targeting RTKs, PI3K, and mTOR. However, 
increasing evidence show that acquired drug resistance is emerging as a significant 
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issue that impedes the clinical success of the PI3K-targeted therapy. Therefore, 
identification of biomarkers to predict clinical response in cancer therapy will be 
pivotal for understanding the resistance mechanisms in PI3K-targeted therapy. 
1.4  Targeting PI3K pathway in cancer therapy 
The PI3K/AKT/mTOR pathway is the most commonly deregulated pathway in 
human cancer (Vivanco and Sawyers, 2002). PI3K is activated by upstream 
activators such as oncogenic receptor tyrosine kinase or RAS. Many components in 
the PI3K-AKT pathway are protein kinases, such as RTKs, PI3Ks, AKT, and mTOR; 
the oncogenic activations of these kinases make them as ideal anti-cancer drug 
targets. Many of PI3K pathway inhibitors are currently in clinical trials and show 
great promise for the treatment of PI3K pathway-addicted tumors (Engelman, 2009). 
As shown in Figure 1.5, inhibitors that target key components in the 
PI3K/AKT/mTOR pathway, including RTKs (such as EGFR, HER2 and VEGFR), 
PI3Ks (such as P110 catalytic subunits and p85 regulatory subunit), AKT and mTOR, 
have very encouraging clinical results in PI3K pathway-targeted therapy (Liu et al., 
2009). However, the efficacy of these targeted agents may have limited clinical 
success due to the complex cross-talks between various pathways and feedback 
loops, resulting in the acquired drug resistance during targeted therapy. Thus, in this 
review I will describe different strategies for targeting PI3K pathway in cancer 
therapy. In addition, we will discuss the molecular mechanisms of acquired drug 
resistance in PI3K-targeted therapy which dramatically leads to limitations of 
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clinical application. 
   
 
Figure 1.5 Targeting the PI3K pathway in cancer. 
Inhibitors in clinical development that target the PI3K or related pathways are shown. EGFR, 
epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; HER2, human 
epidermal growth factor receptor 2 (also known as ERBB2); VEGFR, vascular endothelial growth 
factor receptor (Liu et al., 2009). 
1.4.1 Targeting the RTK-PI3K-AKT in cancer therapies 
Aberrent alterations of RTKs and RAS through somatic mutations and gene 
amplification invariably activate the PI3K pathway. Small molecule RTK inhibitors 
such as EGFR inhibitors (erlotinib and gefitinib) and HER2 inhibitor (lapatinib) are 
the most established targeted therapies in clinical use, which specifically targets 
cancer cell with activating mutations of RTKs. These RTK inhibitors achieve their 
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anti-tumor effects, at least in part, by disabling the PI3K/AKT pathway through 
blocking the signaling from RTKs to PI3Ks (Junttila et al., 2009).  
Although targeting RTKs has become an important therapeutic approach for a 
wide range of human cancers, the effectiveness of such drugs is restricted by the 
development of drug resistance through different mechanisms in human cancer 
(Engelman and Janne, 2008). Multiple mechanisms leading to drug resistance to 
RTK inhibitors have been well-documented, including secondary target mutations, 
gene amplification, and compensatory activation of pro-survival signaling pathways. 
Intriguingly, these mechanisms can occur to the same drug in the same disease. For 
example, secondary mutation in the kinase domain of EGFR (T790M) was found in 
50% of gefitinib-resistant patients, this mutation increases the affinity for ATP as WT 
EGFR and weakens the affinity for EGFR kinase inhibitors (Li et al., 2007; Yun et 
al., 2007). On the other hand, amplification of the MET gene which encodes for the 
receptor tyrosine kinase for hepatocyte growth factor has also been made resistant to 
the EGFR inhibitor (Engelman et al., 2007; Kobayashi et al., 2005; Pao et al., 2005). 
Furthermore, a recent report suggested that multiple RTKs are coactivated to drive 
and maintain downstream signaling to PI3K pathway, thereby limiting the efficacy 
of therapies targeting single RTKs in brain tumor (Stommel et al., 2007). 
Interestingly, all these potential resistance mechanisms lead to constitutive activation 
of the downstream PI3K or MEK signaling pathway (Engelman et al., 2007). 
Conversely, activation of the downstream signaling components (such as AKT and 
MEK) or inactivations of PTEN also result in resistance to RTK inhibitors. Indeed, it 
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has been recently shown that loss of PTEN or activation of PIK3CA in breast 
cancers with amplifications of ERBB2 can confer resistance to trastuzumab 
treatment (ERBB2 inhibitor) by setting a high threshold of Akt activation (Berns et 
al., 2007). Thus, these findings have led to clinical trials using newly designed 
RTK-targeted therapies that can overcome these resistance mechanisms.  
Frequent somatic mutations in the PIK3CA gene which encodes class IA PI3K 
catalytic subunit p110α can lead to constitutive activation of PI3K signaling and 
oncogenic transformation, making PIK3CA a druggable target in cancer therapy (Liu 
et al., 2009). Many PI3K inhibitors have been developed in clinical setting, including 
pan-PI3K inhibitors, and PI3K catalytic isoform-specific inhibitors. Pan-PI3K 
inhibitors target all class IA PI3K catalytic subunits, such as p110α, β, γ and δ 
isoforms. Currently, several pan-PI3K inhibitors, including GDC0941, PX-886, 
BKM120, and XL147 (Ihle et al., 2005; Liu et al., 2009; Markman et al., 2010), have 
entered clinical trials with low toxicity and high anti-tumor activity. In addition, 
isoform-specific inhibitors that selectively inhibit different p110 catalytic subunits 
are under investigation in preclinical studies. For example, CAL-101, a PI3Kδ 
specific inhibitor, is in clinical trials for hematological malignancies (Herman et al., 
2010).  
Despite the promise of PI3K-targeted therapies, an emerging clinical obstacle 
is the acquired resistance to PI3K inhibitors, leading to treatment failure. A recent 
study showed that certain mutations in PIK3CA would confer resistance to the PI3K 
inhibitors (Zunder et al., 2008). Unlike the RTK inhibitor resistant mutations, these 
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PIK3CA mutations did not reside in the classic gatekeeper residues. In addition to 
resistant mutations in PIK3CA, PI3K inhibitors might not effectively down-regulate 
AKT activity in cancers with AKT activating mutations or gene amplification 
(Carpten et al., 2007). Moreover, a feedback upregulation of receptor tyrosine kinase 
ERBB3 expression and activity can also lead to acquired resistance to PI3K 
inhibitors in patients with HER2-overexpression breast cancer (Chakrabarty et al., 
2011). Given the feedback loops attenuate anti-tumor effect of PI3K inhibitor, a 
combined inhibition of PI3K and RTKs may be a potentially useful strategy to 
bypass or prevent drug resistance in the clinic.  
AKT is the most crucial proximal downstream component of the PI3K 
pathway. Both ATP-competitive inhibitors and allosteric inhibitors have been 
developed, including perifosine, MK-2206 and GSK690693 (Hirai et al., 2010; 
Rhodes et al., 2008). These AKT inhibitors could be particularly effective in treating 
cancers harboring mutations and amplifications of AKT or increased pathway 
activity. However, the anti-tumor effects of AKT inhibitors may be attenuated by the 
relief of negative feedback loops. For example, one report shows that AKT inhibitors 
promote RTK expression and activity by activating FOXO and inhibiting mTORC1, 
thereby leading to persistent activation of PI3K-AKT and MEK-ERK pathway 
(Chandarlapaty et al., 2011). On the other hand, Vasudevan and his colleages 
reported that AKT is often not required for proliferation of cancer cells with 
activated PI3K pathway (Vasudevan et al., 2009). In this case, the prevalence and 
dependence of PDK1 in PI3K signaling might substantially affect the clinical 
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outcome of AKT inhibitors. Of notice, PDK1 inhibitors are currently developed as 
anti-cancer agents that have been shown to be effective in vitro and in vivo in cancer 
(Maurer et al., 2009; Peifer and Alessi, 2008). However, the molecular mechanisms 
in which pathway is inhibited by this class of kinase inhibitors remain elusive.  
1.4.2 Utility of mTOR inhibitors in human cancers and resistance 
mechanisms 
Since hyperactivation of the mTOR signaling occurs in diverse human 
malignancies, inhibition of this kinase has became an attractive therapeutic strategy 
to treat cancer (Guertin and Sabatini, 2007, 2009). Rapamycin and its analogues, 
such as RAD001 and CCI-779 (referred to as rapalogs), suppress mTOR activity 
through binding to the FKBP12 binding protein, which in turn interact and inhibit 
mTORC1-mediated phosphorylation of the substrate S6K and 4EBP1 (Alessi et al., 
2009; Guertin and Sabatini, 2009; Meric-Bernstam and Gonzalez-Angulo, 2009). 
Although preclinical studies have shown that members of this class of mTOR 
inhibitors have activity against a number of cancer types, rapalogs have achieved 
limited success as anti-cancer agents. Mechanistically, these rapalogs only inhibit the 
mTORC1 complex, partially reducing phosphorylation of 4EBP1 in most cell 
context (Janes et al., 2010). In addition, inhibition of mTORC1 releases the feedback 
loops that inhibit PI3K-AKT and MAPK-ERK signaling pathways. In many cancer 
cells, this leads to elevated AKT and ERK activity and promotes cell survival 
(Carracedo et al., 2008b; Sarbassov et al., 2006; Sarbassov et al., 2005). These 
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findings provide a strong rationale for dual targeting of mTORC1 and its feedback 
activities. Consistent with this idea, several dual inhibitors of PI3K and mTOR 
activity have been developed including PI-103 and NVP-BEZ235 (Chiarini et al., 
2010; Cho et al., 2010; Fan et al., 2006; Maira et al., 2008). These agents have 
shown greater anti-cancer efficacy compared with those rapalogs. However, the 
clinical therapeutic efficacy and tolerability of such dual PI3K-mTOR inhibitors 
remain to be established. The second-generation ATP-competitive mTOR inhibitors, 
such as PP242 and Torin1, and thus target kinase domain of mTOR, repressing both 
mTORC1 and mTORC2 activity (Dancey, 2010; Janes et al., 2010). Because 
mTORC2 leads to an increase in activation of AKT (Sarbassov et al., 2005), these 
ATP-competitive inhibitors of mTOR maybe superior over rapalogs in cancer 
therapy by blocking the feedback activation of AKT and suppressing 4EBP1 
phosphorylation followed by its downstream effectors. In addition to activating AKT 
and ERK signaling, rapalogs treatment also results in the stimulation of multiple 
other pro-survival feedback loops, including activation of PIM kinase, altered 
expression of eIE4E and 4EBP1, and gene amplification of Myc (Dilling et al., 2002; 
Graff et al., 2008; Hammerman et al., 2005; Ilic et al., 2011). Accordingly, 
pharmacological or genetic inhibition of these pathways has promoted sensitization 
to mTOR-targeted therapy.  
Sensitivity to mTOR inhibitors is thought to be related to dysregulation of 
critical upstream components of PI3K/mTOR pathway. Results from preclinical 
models suggest that genetic alterations and aberrant gene expression resulting in 
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pathway activation correlate with sensitivity to mTOR inhibition. For example, 
HER2 amplification in breast cancer; upregulation of HIF1α; PIK3CA activating 
mutations elevated levels of phosphorylated AKT in many human cancers; and 
Cyclin D1 overexpression have been identified in preclinical models as putative 
predictors of rapalogs response (Brachmann et al., 2009; Hsieh et al., 2010; 
Majumder et al., 2004; Serra et al., 2008; Thomas et al., 2006). However, the use of 
PTEN and PIK3CA alterations and AKT phosphorylation for predicting rapalogs 
sensitivity has not been fully validated. This outcome may be due to the complexity 
of the PI3K/AKT/mTOR signaling network and the existence of feedback loops and 
cross-talk between oncogenic signaling pathways involved in malignant 
transformation, which might determine sensitivity of mTOR inhibitors. Thus, it is 
critical to understand the genetic alterations in human tumors with acquired 
resistance to mTOR inhibitors for insights into additional resistance mechanisms, 
and these findings will provide new effective mTOR-targeted therapies for cancer 
patients.  
1.4.3 Potential clinical implications for targeting PI3K pathway  
Although targeting the PI3K-AKT-mTOR pathway remains a promising 
anticancer strategy, PI3K-targeted inhibitors in clinical development are likely to be 
limited due to the emergence of acquired drug resistance. Acquired resistance can 
reduce the effectiveness of an anti-cancer or render the anti-cancer completely 
ineffective against human malignancies. Identification of reliable biomarkers to 
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predict the treatment response to PI3K-targeted therapies is indeed urgent for the 
successful clinical trials. Therefore, a broader and more systematic interrogation of 
genetic and epigenetic alterations is required to facilitate patient selection and to 
monitor treatment efficacy in clinical use of PI3K inhitiors. In this section, we have 
discussed the most recently identified molecular mechanisms that mediated acquired 
resistance to current PI3K-targeted therapies. The knowledge obtained from these 
studies will help us to design better therapies that prevent and overcome resistance to 
treatment in cancer patients. Furthermore, these insights have prompted the 
development of new PI3K inhibitors. 
While dual PI3K/mTOR inhibitors and ATP-competitive mTOR inhibitors may 
prove more potent as single agents than rapalogs, their greatest efficacy may lie in 
simultaneous targeting of more than one pathway. Mounting evidences indicate that 
anti-cancer efficacy and response duration with inhibitors of a single kinase are 
frequently limited by parallel signaling, bypass pathway activation, or feedback 
activation. Thus, the outcome of ongoing clinical studies of RTKs, PI3K, AKT and 
mTOR inhibitors as well as further testing of the combination of these agents will be a 
key for the development of targeted therapeutics in a wide range of human cancer. 
1.5 Researh objectives 
Genome-wide mapping of genetic and epigenetic alterations has great clinical 
potential for cancer therapies as they give rise to virtually key pathways as potential 
targets. The preliminary purpose of this thesis is to discover the novel tumor 
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suppressor genes silenced by DNA methylation in colorectal cancer. In order to 
achieve this objective, a comprehensive genomic analyses, including gene expression, 
H3K4me3 and DNA methylation, were used in colorectal cancer.  
PP2A complex works as known tumor suppressor gene that regulates variety of 
kinases and oncogenic signaling pathways. However, the oncogenic lesions leading to 
PP2A inactivation in colorectal cancer has not been documented. By using 
intergrative genetic and epigenetic analysis as described above, we have revealed that 
PPP2R2B which encodes a specific PP2A B regulatory subunit was silenced by DNA 
methylation in most of the colorectal cancer. Given the clinical evidence pointing to a 
wide occurrence of PP2A tumor suppressor inactivation has not been previously 
studied in human malignancies, the present study is mainly focused on investigating 
the silencing mechanism and the potential roles of PPP2R2B in CRC. Furthermore, 
this study also aims to investigate the impact of PP2A in oncogenic signaling and 
therapeutic responses to targeted therapy, especially in the known oncogenic 
PI3K/AKT/mTOR signaling pathway. More specifically, the following studies were 
conducted:  
1. To identify novel tumor suppressor genes silenced by DNA methylation; 
2. To determine the silencing mechanism of PPP2R2B, one of CMS genes identified 
by above approach, in colorectal cancer cells;  
3. To identify the potential tumor suppressor function of PPP2R2B in vivo and in 
vitro; 
4. To investigate the potential substrates of PPP2R2B-associated PP2A complexes; 
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5. To investigate the resistant mechanism of mTOR inhibitor rapamycin in colorectal 
cancer and the role of PP2A-PPP2R2B in mTOR inhibitor senstivity;  
6. To determine a novel oncogenic pathway PDK1-Myc, which is closely related to 
the loss of PPP2R2B tumor suppressor function,  in colorectal cancer and the role of 
this pathway in rapamycin sensitivity in cancer therapy; 
7. To examine the combination therapy by using PDK1 inhibitor and mTOR inhibitor 
in colorectal cancer.  
The present study identifies a new tumor suppressor pathway which is 
inactivated in CRC through inactivation of PP2A subunit. Further elucidation of the 
pathway revealed a dysregulated pathway mediated by PDK1, which leads to 
rapamycin resistance in CRC. Thus this project provided a potential therapeutic 



































2.1 Cell lines and cell culture 
2.1.1 Colorectal cancer cell lines 
The human colorectal cancer cell lines HCT116, DLD1, RKO, SW480, HT29, HT15, 
SW403 were purchased from American Type Culture Collection (Manassas, VA) and 
cultured with Dulbecco’s modified Eagle’s media (DMEM), supplemented with 10% 
FBS (Invitrogen). HCT116 cells with genetic disruption of DNMT1 and DNMT3B 
(HCT116 DKO) were kindly provided by Dr. Bert Vogelstein (Johns Hopkins 
University, Baltimore, MD) (Rhee et al., 2002) and cultured in the same medium as 
colorectal cancer cell lines.  
2.1.2 Other cell lines  
The immortalized human embryo kidney epithelial cells (HEK-TERV) were kind 
gifts from Dr. W.C. Hahn at Dana-Farber Cancer Institute (Chen et al., 2004). 293T 
and the immortalized human mammary epithelial cells (MCF-10A) were purchased 
from the American Type Culture Collection (Manassas, VA) and were maintained in 
culture as recommended by ATCC. The human hepatocellular carcinoma cell lines 
(HCC) Hep3B, HepG2, hUH7 and human osteosarcoma cells U2OS were were 
routinely maintained in DMEM media with 10% fetal bovine serum (FBS; 
Invitrogen). Ovarian cancer cells OVCAR3, OVCAR5, SK-OV-3 and Human renal 
cell carcinoma (RCC) cell lines 786-O and Caki-2 were used and culture with RPMI 
1640 medium supplemented with 2mM L-glutamine, 10µg/ml insulin and 5% fetal 
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bovine serum. All cells were cultured at 37°C in a 5% CO2 humidified incubator.  
2.2 Patient tumor and normal samples  
Colorectal primary tumors and matched adjacent non-malignant colon tissues were 
obtained from Singapore Tissue Network in accordance with the local ethics 
committee. All tissue samples were harvested after obtaining written informed 
consent from patients. Normal colon DNA samples were purchased from Stratagene 
(Stratagene, La Jolla, CA).  
2.3 Drugs and chemicals 
5-aza-2’-deoxycytidine(5-AzaC) and Doxycycline were purchased from 
Sigma-Adrich (St.Louis, MO) and prepared in sterile distill water. Rapamycin and 
PI-103 were purchased from Alexis (San Diego, CA). PDK1 inhibitor BX912 and 
the PIK3CA inhibitor PIK90 were obtained from Axon Medchem (Groningen, 
Netherlands). All kinase inhibitors were dissolved in dimethyl sulfoxide (DMSO). 
2.4 RNA analysis 
2.4.1 Total RNA isolation 
Total RNA was isolated by homogenizing cells in TRIzol (Invitrogen) followed by 
subsequent purification using the RNeasy Mini kit (Qiagen, Valencia, CA) according 
to the manufacturer’s protocol. In brief, cells were lysed with 1ml TRIzol and 200µl 
chloroform. The supernant layer containing RNA was separated by centrifuge and 
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mixed with equal volume of 70% ethnol. The mixtures were purified with RNeasy 
Mini kit and RNAs were eluted into 30µl RNase-free water. The concentration and  
qualitity of the total RNA were determined by a NanoDrop (ND-1000) (NanoDrop 
Technologies, Delaware, USA). Extracted RNAs were stored at -80C.  
2.4.2 Reverse transcriptase (RT) 
The cDNA was synthesized using the High Capacity cDNA Reverse Transcription 
Kit (ABI) according to the manufacturer’s instructions. Briefly, 1.0µg of total RNA 
was reverse transcribed into complementary DNA (cDNA) in a 20µl reaction 
mixture consisting of RT Buffer, dNTPs, random primers and Multiscribe reverse 
transcriptase, incubated at 25C for 10 minutes and then at 37C for 2 hours. The 
products of RT were further processed by gel-based semi-quantitative RT-PCR or 
quantitative real-time PCR. 
2.4.3 Polymerase chain reaction (PCR) 
2.4.3.1  Gel-based semi-quantitative RT-PCR 
RT-PCR was carried out in a thermocycler machine (DNA Engine DYAD, Bio-Rad) 
in a final volume of 12.5µl reaction containing 1.0µl of synthesized cDNA 
(100ng/reaction) as template, 0.6µM of each forward or reverse primers (Table2.1), 
and 9.5µl of Taq-Gold PCR master mix (ABI). The conditions of PCR program were 
dependent on the specificity of PCR primers. GAPDH or ACTIN were used as 
internal control. The PCR products were visualized by 2% DNA agarose gel 
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electrophoresis.  
Table 2.1 Oligonucleotide primers for RT-PCR 
Table 2.1 Oligonucleotide primers for RT-PCR 
Name Direction sequence  
SFRP1 Forward 5' TCGGCCGCGAGTACGACTA 3' 
  Reverse 5' TCTTGTAGCCCACGTTGTGG 3' 
CDH2  Forward 5' CCCTGCTTCAGGCGTCTGTA 3' 
  Reverse 5' CATGCCATCTTCATCCACCT 3' 
THY1 Forward 5' GACCCGTGAGACAAAGAAGC 3' 
  Reverse 5' GCCCTCACACTTGACCAGTT 3'  
RASD1 Forward 5' GAACTGCTATCGCATGGTCA 3' 
  Reverse 5' AACGTCTCCTGTGAGGATGG 3' 
HAND1  Forward 5' AGTGGGCTGCGCGTCTCATTTTC 3' 
  Reverse 5' AAGGGTTCGTGGAGCATGGG 3' 
DDIT4L  Forward 5' ATGGTTGCAACTGGCAGTTTG 3' 
  Reverse 5' AGGACCTTTGAGCAACCAAG 3' 
ADRB2  Forward 5' AACGGCAGCGCCTTCTTGCT 3' 
 Reverse 5' GGCCCATGACCAGATCAGCA 3' 
PPP1R3C  Forward 5' ATGAGCTGCACCAGAATGATCC 3' 
  Reverse 5' TTGGTTGTGTGAGCACTTCC 3' 
PPP2R2B  Forward 5' ATGGAGGAGGACATTGATACC 3' 
 Reverse 5' ACATTGTATTCACCCCTACG 3'  
SOX17  Forward 5' ATACGCCAGTGACGACCAGAGC 3' 
 Reverse 5' TAGCCCACACCATGAAAGCG 3' 
GAPDH Forward 5' ATGGGAAGGTGAAGGTCGG 3' 
 Reverse 5' AAGACGCCAGTGGACTCCACGA 3' 
ACTIN Forward 5' GTGGGGCGCCCCAGGCACCA 3' 
  Reverse 5' CTCCTTAATGTCACGCACGATTTC 3' 
 
2.4.3.2  Quantitative real time PCR  
Quantitative real-time PCR of PPP2R2B or Myc was performed on a PRISM 7900 
Sequence Detection System (Applied Biosystems) using TaqMan probe of PPP2R2B 
(Assay ID: Hs00270227_m1, Applied Biosystems) and Myc (Assay ID: 
Hs00905030_m1, Applied Biosystems) with Taqman fast universal PCR Master mix 
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kit (Applied Biosystems). Three independent experiments were performed and 
samples were normalized to the levels of GAPDH mRNA (Taqman®GAPDH control 
reagent of human). Data was analyzed by using ABI SDS 2.2 software (Applied 
Biosystems). 
2.4.4 Microarray analysis 
Total RNA was subjected to reverse transcription to synthesize the first-strand cDNA 
and amplify the second-strand cDNA synthesis by using the Illumina® TotalPrep™ 
RNA Amplification kit (Ambion, USA) according to the manufacturer’s protocols. 
The resultant amplified RNAs were hybridized on the Sentrix® HumanRef-8_V2 
Expression BeadChip which covered approximately 24,000 RefSeq transcripts for 
whole-genotyping expression assay (Illumina, USA). The beadChip was washed and 
scanned with Illumina BeadStation according to the Illumina protocols. Microarray 
scanned images were imported to Illumina® GenomeStudio for data quality control 
and the raw data was analyzed with GeneSpring GX 11.0.2 (Agilent Technologies) 
(software settings: Lower cutoff for 'Present' call: 0.95; Upper cutoff for 'Absent' call: 
0.6; Threshold raw signal to: 10; Normalization algorithm: Quantile; Baseline 
Transformation: median of all samples), the gene expression level data file were 
transformed to log2 values and quantile normalized. Significant genes were selected 
based on a minimum 3 fold change and FDR < 0.1%. Unsupervised hierarchical 
clustering analysis for the significant genes was performed using Cluster and 
visualized using TreeView.  
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2.4.5 Gene ontology analysis and clinical relevance analysis 
The colon cancer methylation silencing genes (CMS)  were imported to Ingenuity 
Pathway Analysis (www.ingenuity.com) for gene ontology (GO) analysis and 
analyzed results showed the GO biological functions and potential signaling 
pathways involved. To get the information of gene expression pattern on published 
databases, we examined the PPP2R2B expression level in Oncomine database 
(www.Oncomine.org). Oncomine provides web-based cancer/normal microarray 
database (Rhodes et al., 2004a, b). The expression level of PPP2R2B in each cancer 
vs normal database was exported as box plots.  
2.5 Chromatin immunoprecipitation (ChIP)-sequencing 
assay 
2.5.1 Chromatin immunoprecipitation 
ChIP assays with HCT116 and DKO cells were carried out as following: Cells were 
cross-linked with formaldehyde (Sigma-Aldrich) directly to culture medium to a 
final concentration of 1.0% for 10 min at room temperature. Formaldehyde was 
inactivated by addition of 200mM glycine. After wash with ice-cold PBS, cells were 
harvested and lysed in ChIP lysis buffer followed by sonication to shear the 
chromatin-DNA. Chromatin extracts containing DNA fragment of average size of 
500 bp were immunoprecipitated using anti-H3K4me3 (Upstate) and rabbit IgG 
(Santa Cruz). After a series of washing with wash buffers, the DNA-protein complex 
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was eluted in ChIP elution buffer and the DNA was extracted by 
Phenol:Chloroform:IAA (Ambion). The purified ChIP-DNA was dissolved in TE 
buffer and ready for ChIP-seq experiments. 
2.5.2 ChIP-seq 
Purified immunoprecipitated DNA was prepared for sequencing according to a 
modified version of the solexa genomic DNA protocol. Briefly, fragmented DNA 
was end paired and subjected to 15 cycle of linker-mediated (LM)-PCR using Oligos 
purchased from Illumina. Amplified fragments between 200 and 300 bp were 
isolated by agarose gel electrophoresis and purified. The fragment DNA size was 
confirmed by Agilent DNA chip analysis. Ten nanograms of linker-ligated DNA 
were applied to the flow-cell using the Solexa Cluster Station fluidics device. 
Samples were then subjected to 36 bases of sequencing according to Illumina’s 
standard protocols. The data generated from Solexa Genome Analyzer instrument 
will undergoes ChIP-seq pipeline, manage by the Research Computing group. 
2.6 DNA analysis 
2.6.1 Purification of genomic DNA 
Genomic DNA was extracted from cell pellets according to the recommended 
protocol from the QIAamp® DNA Mini Kit (QIAGEN). The cell pellets were 
resupsended in 200µl of 1X PBS and 20µl of proteinase K. The samples were further 
mixed and washed in the spin column with buffers provided after which the DNA 
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was eluted in sterile distilled water. 
2.6.2 DNA bisulfite treatment  
Bisulfite modification of DNA was performed by using the EZ DNA 
methylation-Gold kit (ZYMO Research) according the manufacture’s instructions. 
Briefly, 1.0µg of gemomic DNA in 20µl distilled water was added to 130µl of 
conversion treatment reagent and EZ DNA PCR program was carried out at 98°C for 
10mins, followed by 8 cycles of 53C for 30mins, 53°C for 6mins and 37°C for 
30mins. After EZ DNA program, 600µl M-Binding buffer was added into 
Zymo-Spin IC Column and place the column into provided collection tube and the 
PCR samples were loaded into the column and centrifuged at full speed >10000×g 
for 30secs. The columns were washed with 200µM Desulphonation buffer and 200µl 
M-Wash buffer to the column. Bisufited DNAs were eluted with 10µl M-Elution 
buffer and stored at -20°C for DNA methylation analysis. 
2.6.3 DNA promoter and CpG island prediction 
DNA promoter was identified and downloaded from genotype database in Genaltas 
(http://genatlas.medecine.univ-paris5.fr) and the CpG island of promoter was 
predicted by using CpG island searcher: 
http://www.uscnorris.com/cpgislands/cpg.cgi or Methyl Primer Express 
v1.0.(Invitrogen).  
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2.6.4 DNA methylation analysis 
The CpG island DNA methylation status was determined methylation-specific PCR 
(MSP) and bisulfite genomic sequencing (BGS). MSP and BGS primers were 
designed by using Methyl primer express v1.0 (Invitrigen) and synthesized. MSP 
and BGS were performed in a 12.5μl reaction mixture consisting of 0.6μM of each 
primers targeting specific DNA promoters (Table2.2), 0.2mM dNTP, 1.5mM MgCl2, 
1×PCR buffer, 0.5unit Gold-Taq (Applied Biosystems) and 0.5μl of bisulfited 
template DNA. PCR program was carried out at 95oC for 10 min, followed by 40 
cycles of 94oC for 30 s, 60oC for 30 s, 72oC for 30 s and a final cycle of 72oC for 10 
min (MSP) or 30 min (BGS). The PCR products were analyzed on 2.0% agarose gels. 
The MSP results of selected samples were confirmed by bisulfite genomic 
sequencing. BGS PCR products are ligated with TA cloning vector (PCR2.1–TOPO, 
invitrogen) and transformed with TOP-10 competent cells (Invitrogen). 10 clones are 
chosen for sequencing and the methylation ratio of each CpG site is tabulated.  
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Table 2.2 Oligonucleotide primers for Methylation-specific PCR and Bisulfite 
genomic sequencing. 
Name Direction sequence   
SFRP1 M  Forward 5' TGTAGTTTTCGGAGTTAGTGTCGCGC 3' 
  Reverse 5' CCTACGATCGAAAACGACGCGAACG 3' 
SFRP1 U  Forward 5' GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT 3' 
 Reverse 5' CTCAACCTACAATCAAAAACAACACAAACA 3' 
CDH2 M Forward 5' AGTACGTACGATTCGGAGC 3' 
  Reverse 5' GCGAAAAATACAACGACG 3' 
CDH2 U  Forward 5' TGTAGTATGTATGATTTGGAGT 3' 
 Reverse 5' ACCACAAAAAATACAACAACA 3' 
HAND1 M  Forward 5' CGTTTTTAGGTTTCGGTGC 3' 
  Reverse 5' CGACGAATTTATTCCCGACT 3' 
HAND1 U Forward 5' GTGTTTTTAGGTTTTGGTGT 3'  
 Reverse 5' TCAACAAATTTATTCCCAACT 3' 
DDIT4L M  Forward 5' GTCGTGTATTCGGAATTGC 3' 
  Reverse 5' ATAACCTCCGAAACAACGAA 3' 
DDIT4L U  Forward 5' GAGTTGTGTATTTGGAATTGT 3' 
 Reverse 5' ACATAACCTCCAAAACAACAAA 3' 
THY1 M  Forward 5' TATTTTTATATTAATGCGGGATCGT 3' 
  Reverse 5' CGATTACTACACCCAACTCGAA 3' 
THY1 U  Forward 5' TTATTTTTATATTAATGTGGGATTGT 3' 
 Reverse 5' TCCAATTACTACACCCAACTCAAA 3' 
RASD1 M  Forward 5' AGAGGGATAGGGGTATCGTC 3 
  Reverse 5' CCTCCCAACTCGATACGT 3' 
RASD1 U  Forward 5' GTAGAGGGATAGGGGTATTGTT 3' 
 Reverse 5' ACCCTCCCAACTCAATACAT 3' 
PPP1R3C M  Forward 5' CGGATATATCGGGTAATGAAC 3' 
  Reverse 5' CGTACCGCATACAACGAAC 3'  
PPP1R3C U  Forward 5' ATGTGGATATATTGGGTAATGAAT 3' 
 Reverse 5' CATACCACATACAACAAACACC 3' 
ADRB2 M  Forward 5' GGTAGAACGTATTGCGAAGC 3'  
  Reverse 5' GAAACTCTACGAACCGCG 3' 
ADRB2 U  Forward 5' GGGTAGAATGTATTGTGAAGT 3' 
 Reverse 5' CAAAACTCTACAAACCACA 3' 
PPP2R2B M  Forward 5' AGTAGTAGTTGCGAGTGCGC 3' 
  Reverse 5' GAACAACCGCGACAAAATAAT 3' 
PPP2R2B U Forward 5' AGTAGTAGTAGTTGTGAGTGTGT 3' 
 Reverse 5' AAACAACCACAACAAAATAATACC 3' 
SOX17 M Forward 5' ACGTGGGATTCGGATTAC 3' 
  Reverse 5' CGCCCGTATTCTAACCTATC 3 
SOX17 U Forward 5' GATGTGGGATTTGGATTAT 3' 
  Reverse 5' CCACCCATATTCTAACCTATC 3' 
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PPP2R2B BGS Forward 5' ATTATTGTTGTTGGGAAAGA 3' 
  Reverse 5' CAAAATAATACCTTTCTAAACCC 3' 




2.7 Plasmid Construction 
2.7.1 Mamalian expression plasmid construction 
The human full-length HAND1, RASD1 and THY1 cDNA were isolated by RT-PCR 
using 100ng total RNA from normal colon tissue (BD bioscience) with gene cloning 
primers with indicated restriction enzyme sites (Table 2.3). The PCR products were 
cloned into mammalian expression vector pcDNA4/Myc/hisB (Figure 2.1). 
 
Table 2.3 Oligonucleotide primers for expression vector construction 
HAND1  Forward 5' GGTACCACCATGAACCTCGTGGGCAGCTA 3' 
  Reverse 5' GAATTCCACTGGTTTAACTCCAGCG 3' 
THY1 Forward 5' GGTACCACCATGAACCTGGCCATCAGC 3' 
 Reverse 5' GAATTCCACAGGGACATGAAATCCGTG 3' 
RASD1  Forward 5' GGTACCACCATGAAACTGGCCGCGATGA 3' 
  Reverse 5' GAATTCCAGCTGATGACGCAGCG 3' 
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The human Full-length PPP2R2B coding region was isolated by RT-PCR using 100 
ng total RNA from normal colon tissue and the following primers with indicated 
restriction enzyme site at 5′ and 3′ respectively: Forward primer with KpnI 
5′-GGTACCACCatggaggaggacattgatacc-3′ and Reverse primer with  XhoI 
5′-CTCGAGCAgttaaccttgtcctgga-3′. The PCR product was cloned into 
pcDNA4/myc-hisB (Figure 2.1) between Kpn I and Xho I sites for overexpression 
studies or pcDNA4/TO/myc-hisB for inducible system (Figure 2.2). The human 
full-length PDK1 was amplified by RT-PCR using 100ng total RNA from HEK293 
cells and the following primers with EcoRI restriction enzyme site: 
5’-tcGAATTCgccaggaccaccagccagc-3’ and 5’- GAGAATTCctgcacagcggcgtccgg-3’. 
The PCR product was cloning into pHA.CE vector (Figure 2.3) between EcoRI and 
sequenced. To generate PPP2R2B retroviral expression vector, myc-tagged 
PPP2R2B fragment was subcloned into pMN-IRES-GFP vector (Figure 2.4) (a kind 











Figure 2.1 Map of mammalian expression vector pcDNA4/myc-his 
Type B was used in this thesis. Gene of interest was inserted into multicloning sites(MCS) and 
fused with myc-tagged.  
 
 
Figure 2.2 Map of mammalian expression vector pcDNA4/TO/myc-his in 
T-REx™ system 
Type B was used in this thesis. Gene of interest was inserted into multicloning sites(MCS) and 
fused with myc-tagged. 
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Figure 2.3 Map of mammalian expression vector pHACE with C-terminal HA 
tag 
This vector was constructed from pcDNA3 as vector backbone. PDK1 fragment was inserted 
into EcoRI cloning site without start codon ATG and stop codon. The mammalian antibiotic 
selection marker is Neomycin.  
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Figure 2.4 Schematic view of retroviral expression vector with PPP2R2B gene. 
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2.7.2 Construction of pSIREN-RetroQ-ZsGreen1 Vector targeting 
PPP2R2B 
PPP2R2B siRNA sequence containing 19bp nucleotides were input into online 
shRNA sequence designer provided by Clontech 
(http://bioinfo.clontech.com/rnaidesigner). shRNA forward and reverse primers with 
MluI site are list in Table 2.4 
 





shRNA targeting PPP2R2B was constructed into pSIREN-RetroQ-ZsGreen1 vector 
(Figure 2.5) according to the manufacturer’s protocol. Briefly, forward and reverse 
primers were annealed to double-strand oligonucleotide and ligated with 
pSIREN-RetroQ-Zsgreen1 vector. shRNA plasmid DNA was selected by single 




Figure 2.5 Map of RNAi-Ready pSIREN-RetroQ-ZsGreen vector. 
Annealed double-strand oligonuleotide shRNA was inserted between BamH I and EcoRI sites. 
The selection marker of this vector is ZsGreen.  
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2.8 Generation of stable cell lines 
2.8.1 Tet-on inducible Cell lines  
Tet-on inducible cell lines were constructed with T-REx™ System (Invitrogen) 
according to the protocol. Tetracycline regulation in the T-REx™ System is based 
on the binding of tetracycline to the Tet repressor and derepression of the promoter 
controlling expression of the gene of interest. To generate the PPP2R2B Tet-on 
inducible cell lines, colon cancer cells DLD1 or HCT116 were transfected with 
pcDNA6.0/TR (Figure 2.6), followed by selection with Blasticidin (10μg/ml) 
according to the protocols of T-Rex system kit (Invitrogen), and then transfected 
with the pcDNA4/TO/PPP2R2B-myc or empty control vector and selected for 
Zeocin (100μg/ml). The generated clones were screened for doxycycline inducible 
expression of PPP2R2B by using immunoblotting analysis with anti-myc antibody. 
For doxycycline treatment, inducible cells were treated with doxycycline to a final 
concentration of 1μg/ml. positively identified clones were expanded and maintained 





Figure 2.6 Map of pcDNA6/TR vector of Tet-on inducible system. 
It expresses the E. coli Tn10-encoded tetracycline repressor which will bind to the Tet operator in 
pcDNA4/TO/myc-hisB. The mammalian antibiotic selection marker is blasticidin. 
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2.8.2 Stable cell lines construction 
To make PPP2R2B retroviral stable expression cell lines, Plat A retroviral packaging 
cells (Cell Biolab, San Diego, CA) were transfected with pMN-PPP2R2B or pMN 
empty vector by using Lipofectamine 2000 (Invitrogen). After 48 hours of 
posttransfection, the retroviral particles containing PPP2R2B were infected targeting 
cells HT29 or SW480 with polybrene (8μg/ml). Stable retroviral cell lines were 
amplified and selected by sorting with GFP for further analysis.  
2.9 Flow cytometry analysis  
Cell cycle analysis was done by DNA content quantification. Briefly, cells were 
seeded into 6-well plate and treated with indicated drugs for different time points. 
The cells were harvested by trypsin and fixed with 70% ethanol for 1 hr at 4oC. The 
fixed cells were washed twice with cold PBS, treated with 100µg/ul of RNaseA for 5 
min and stained with 50μg/ml of propidium iodide (PI) for 30 min under light 
protection. The stained cells were analyzed by FACScalibur (BD Bioscience) and 
quantified by using CellQuest software (BD bioscience).  
 
For BrdU incorporation assay, cells were treated as above and incubated with BrdU 
reagent for 5 hours before harvesting. Cells were fixed and stained with the BrdU 
antibody and 7-AAD according to the manufacture’s protocol (BD Bioscience). 
Stained cells were analyzed by FACScalibur (BD Bioscience) and quantified by 
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using CellQuest software (BD Bioscience).  
2.10 Cell viability/proliferation assay  
Cell viability was measured using CellTiter-Glo™ Luminescent Cell Viability Assay 
(Promega, Madison, WI) according to manufacturer’s instructions. This assay is a 
homogeneous method of determing the number of viable cells in culture based on 
quantification of the ATP present, which signals the presence of metabolically active 
cells. In brief, 1000 cells/well were seeded in 96-well white flat-bottom plate (Costar) 
with 100µl medium. After drug treatment for the indicated days, cells were lysed by 
50µl of CellTiter-Glo® reagent and the luminescence signals were measured by 
using Microlumat Plus LB96V system (Berthold Technologies). 
2.11 Cell Senescence-associated β-galactosidase staining 
assays  
Cell senescence assay was performed according to the protocol of Senescence 
Detection kit (BioVision, Mountain view, CA). Senescence cells display increase of 
cell size, senescence-associated expression of β-galactosidase (SA-β-Gal) activity 
and altered patterns of gene expression. This assay hisochemically measures the 
SA-β-Gal activity in cultured cells to detect the senescence cells. In detail, 
DLD1-PPP2R2B inducible cells were seed in 6 well and treated with 1.0µg 
Doxycycline at indicated days. Cells were washed once with PBS and fixed with 
Fixative Solution for 15 minutes at room temperature. Fixed cells were washed twice 
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with PBS and stained with 0.5ml Staining Solution Mix (470µlof staining solution, 
5µlof staining supplement and 25µl of 20mg/ml X-gal in DMF) for overnight at 
37oC. Stained cells were photographed under a microscope for development of blue 
color.  
2.12 Colony Formation Assay in monolayer and soft agar  
Monolayer colony formation assays were performed to evaluate cancer cell growth 
in vitro, DLD1 and HCT116 cells were plated at 3.0×105 per well using 6-well plates, 
and transfected with either pcDNA4-PPP2R2B or backbone pcDNA4 (2.0μg) using 
Fugen 6 (Roche) according to the manufacturer’s protocol. The cells were replated in 
triplicates and cultured for 10–15 days in complete DMEM medium containing 
Zeocin (100μg/ml) and stained with gentian violet after methanol fixation. For 
DLD1 and HCT116 inducible cells foci formation assay, 1×104 cells were seeded on 
6-well plate with or without treatment with Dox or rapamcycin. Cells were grown 
for 2 weeks and the surviving colonies were stained with gentian violet after 
methanol fixation, and visible colonies (>50 cells) were counted. Soft agar colony 
formation assay was used to measure the ability of anchorage-independent growth in 
vitro. For anchorage-independent growth of inducible cells, cells were suspended in 
complete DMEM containing 0.3% agar with or without doxycycline and layered on 
complete DMEM containing 0.6% agar in 6-well plate. After 3-4 weeks, colonies 
were stained with iodonitrotetrozolium chloride (Sigma) for overnight. Colonies 
from randomly-selected image areas of three replicate wells were enumerated and 
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three independent experiments were performed. 
2.13 RNA interference 
2.13.1 siRNA transient transfection 
Specific siRNA oligos targeting Myc, p70S6K, PPP2R1A, AKT1, PIK3CA, PDK1, 
mTOR, raptor and rictor mRNAs were described previously (Cappellen et al., 2007; 
Heinonen et al., 2008; Sablina et al., 2007; Sarbassov et al., 2005; Vasudevan et al., 
2009) (Table2.5). PIK3CB siRNA was purchased from Santa Cruz Biotech. The 
SMARTpool® siRNA targeting PPP2R2B and the non-targeting control were 
purchased from Dharmacon (Lafayett, CO). A separate PPP2R2B siRNA targeting 
the following sequence: 5’- GCUUACUUUCUUCUGUCUA-3’ was obtained from 
Sigma-Proligo. Cells were transfected with 100nM final concentration of siRNA 
duplexes using Lipofectamine RNAiMAX (Invitrogen) following the manufacturer’s 
instructions.  
Table 2.5 List of siRNA sequence for the functional study 
 
Gene ID Symbol Sequence  Ref. 
NM_002467 Myc GGTCAGAGTCTGGATCACC (Cappellen et al., 2007) 
J02902 PPP2R1A GACAACAGCACCTTGCAGAGT (Sablina et al., 2007) 
NM_003161 P70S6K GGACATGGCAGGAGTGTTT (Heinonen et al., 2008) 
NM_006218 PIK3CA AATGAAAGCTCACTCTGGA (Vasudevan et al., 2009) 
NM_005163 AKT1 CGCGTGACCATGAACGAGT (Vasudevan et al., 2009) 
NM_002613 PDK1-1 GCAGCAACATAGAGCAGTACA (Vasudevan et al., 2009) 
NM_002613 PDK1-2 CAAAGTTCTGAAAGGTGAAAT (Vasudevan et al., 2009) 
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2.13.2 Stable RNA interference system 
shRNA vector PLKO.1 targeting human mTOR, Raptor, Rictor, PDK1, scramble 
shRNA plasmid, psPAX2 packaging plasmid and pMD2.G envelope plasmid were 
purchased from Addgene (Cambridge, MA). To generate PPP2R2B shRNA stable 
cells, ShRNA vector pSIREN-RetroQ-ZsGreen1 targeting human PPP2R2B was 
transfected into PlatA packaging cell using Lipofectamine 2000 (Invitrogen). At 48 
hr posttransfection, viral supernatants were passed through a 0.45μm nitrocellulose 
filter and were used to infect HEK-TERV cells with polybrene (8μg/ml). Stable 
retroviral cell lines were selected by sorting with GFP for further analysis. To 
generate mTOR, Raptor, Rictor and PDK1 shRNA stable cells, the human 
embryonic kidney 293T cells were used for production of lentivius. PLKO.1 shRNA 
vectors targeting mTOR, Raptor, Rictor and PDK1 were transfected into 293T cells 
along with psPAX2 and pMD2.G by using lipofectamine2000. Procedure for 
infection is the same as retroviral infection. After infection with these shRNA 
lentivirus, the target cells were selected with 1.0µg/ml puromycin (Sigma) for 7 days 
and pooled for experiments.  
2.14 Western blot analysis 
Cells were harvested and washed twice with cold PBS. Cells were lysed with 
Radioimmunoprecipitation assay (RIPA) lysis Buffer (50mM Tris-HCl, 1mM EDTA, 
150mM sodium chloride, 1.0% NP40, 0.5% sodium deoxycholate and complete 
protein inhibitor cocktail (Roche)). Cells were lysed on ice before being centrifuged 
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at 13,200 rpm for 15 min at 4°C. Protein concentrations in the supernant were 
determined by the Bradford Protein Assay Kit (BIO-RAD, Hercules, CA). Protein 
samples were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) with a mini-gel apparatus (Mini-Protean II, BioRad 
Laboratories, Hercules, CA). The percentage of SDS-polyacrylamide gel was 
adjusted according to the protein molecular weight. After protein separation by 
SDS-PAGE, proteins were transferred onto a PVDF immunobilon membrane 
(Millipore, Billerica, MA ), and the nitrocellulose membrane was blocked in 5% 
non-fat milk in Tris-buffered saline-Tween 20 (TBS-T). After blocking, the 
immunobilon membrane was blotted with specific primary antibodies followed by 
HRP-labelled secondary antibodies (GE healthcare, UK). Primary antibodies used in 
this thesis for western blot were: Myc, p-Myc(T58/S62), p70-S6K, 
p-p70S6K(T421/S424), p-p70S6K(T389),  p-p70S6K(S371),  p-AKT (S473), 
p-AKT (T308), p-PDK1(S241), S6, p-S6(S235/236), p-MEK1/2(S217/221), 
p-ERK1/2(T202/Y204), p-p38MAPK(T180/Y182), PP2A A Subunit(81G5), p110α 
and p110β (Cell Signaling Technology, Danvers, MA). β-catenin and PDK1 (BD 
Biosciences), and anti-PP2A B subunit (B55) (Upstate Biotechnology); 
α-HA(SC-805) and β-Actin (Santa Cruz Biotech) and Myc (9E10) (Sigma-Aldrich). 
ECL anti-rabbit (NA934V, GE Healthcare, UK) and ECL anti-mouse (NA931V, GE 
Healthcare, UK) horseradish peroxidise-linked whole antibodies were as secondary 
antibodies. Chemiluminescence was detected by ECL Plus Western Blotting 




For immunoprecipitation analysis, 293T cells were transiently transfected with 
HA-PDK1 and PPP2R2B-Myc by using Fugen HD (Roche). After 48 hr of 
posttranfection, the cells were lysed with Lysis Buffer (50mM Tris-HCl, 150mM 
sodium chloride, 1.0% NP40, 0.5% sodium deoxycholate and complete protein 
inhibitor cocktail(Roche)). The cell lysates were precleared by incubating with the 
protein A/G agarose for 3 hr under the rocking condition at 4°C . Precleared 
supernatant collected were then incubated with protein G/A agrarose and 2-5µg of 
pull-down antibodies such as anti HA-tag (SC-805, Santa, Cruz) or Myc-tag (9E10, 
Roche) and normal IgG Mouse/Rabbit (depending on the species of pull down 
antibody used) on the rotator overnight at 4°C. The unbound complexes were 
removed through three times washing with ice-cold buffers suggested in the protocol. 
The supernatant were removed after the last wash. Agarose beads which bound with 
the proteins were stained with SDS-PAGE loading dye mixed with DTT reducing 
reagent before resolving the precipitated complexes using SDS-PAGE gel 
electrophoresis and western blotting. To study direct interaction between B55β-Myc 
and endogenous PDK1, DLD1-PPP2R2B cells were treated with Dox for 24 hr and 
cells were lysed and immunoprecipitated with anti-PDK1 and anti-Myc-tag. 
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2.16 Protein phosphatase activity assay 
PPP2R2B-associated PP2A phosphatase activity was measured by using the PP2A 
Immunoprecipitation Phosphatase Assay Kit (Millipore). In detail, DLD1-PPP2R2B 
or DLD1 control cells were suspended in lysis buffer (50mM Tris-HCl, pH 7.4, 
7.5% Glycerol, 1mM EDTA, 150mM NaCl, 0.5% NP-40, 1mM Na3VO4, Complete 
Protease Inhibitor), cleared from debris by centrifugation, incubated with c-Myc 
(9E10, Roche) followed by incubation with protein A agarose(Roche) for overnight 
at 4oC. The beads were washed with TBS 3 times and followed by one wash with 
Ser/Thr Assay buffer. 60µl dissolved phosphopetide (K-R-pT-I-R-R) and 20µl 
Ser/Thr Assay buffer were added to the beads and incubated by shaking for 10 
minutes at 30oC. After briefly centrifuged, 25µl supernant was added to 96-well 
microtiter plate and mixed with 100µl of malachite Green Phosphate Detection 
Solution. Fluorescence was measured using a fluorescence microplate reader 
(Sunrise, Tecan) at 650nm wave. 
2.17 Immunofluorescence Analysis 
The cells were seeded on the glass slides in 12 well plates. After treatment with Dox 
for 48 hrs, cells were fixed with 3.7% paraformaldehyde in PBS and permeablized 
with 0.2% Triton-X100. Cells were sequentially incubated with primary antibodies 
(anti-Myc or anti-p-PDK1(S241) and Alexa Fluor 488 or Alexa Fluor 
546-conjugated secondary antibodies (Invitrogen) for 1 hour each and 
4',6-diamidino-2-phenylindole (DAPI) for nuclear staining for 15 mins. They were 
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then mounted in Fluorsave (CalBiochem) mounting medium. The stained cells were 
examined by Zeiss LSM510 confocal microscopy. 
2.18 Mouse Xenografts and Drug Treatment 
The female athymice BALB/c nude mice (5-8 week-old) were housed in the 
Biological Resource Centre. Mice were implanted subcutaneously in both sides of 
flank with 3×106 DLD1-PPP2R2B or control DLD1 cells, respectively. When 
tumors reached ~70 mm3, the mice were divided two groups (8 mice per group) and 
the doxycycline was administrated by oral gavages at 100mg/kg daily. Tumor 
progress was monitored by whole body weights and tumor size measurements every 
other day. For combination treatment with rapamycin and doxycycline, the same 
dose of doxycycline was given every other day and rapamycin was administered by 
intraperitoneal injection at 4mg/kg at Day 3, 5, 7 and 11. Tumor diameters were 
measured every 3-4 days with caliper and tumor volumes were calculated per data 
time point. Statistical analysis was carried out using independent t-test, P value 
<0.05 was considered significant. All animal work was performed in accordance 
with animal experiments guidelines of Singapore. 
2.19 Statistical analysis 
All values from in vitro assays are expressed as mean ± SD or SEM of at least three 
independent experiments, unless otherwise states. P values were calculated with the 









3 Chapter III: Integrative genomic and epigenomic 














3.1 Introduction  
 Genetic and epigenetic alterations have been associated with tumor formation 
and progression. Recent evidence indicates that tumor suppressor genes are 
frequently inactivated due to epigenetic changes rather than somatic mutations 
during cancer development. For instance, Schuebel KE et al has observed a higher 
frequency of DNA methylation associated gene silencing as compared to those 
somatic mutation associated gene inactivation in colon cancer (Schuebel et al., 2007). 
This finding was further supported by integrative genomic analyses in ovarian cancer, 
which identified the frequency of DNA methylation silenced genes was higher than 
gene inactivation by somatic mutations (2011). Furthermore, the authors also 
reported that the high occurrence of DNA methylation was correlated with silencing 
of various tumor suppressor genes, which led to dysregulation of pathways such as 
Rb, RAS/PI3K and Notch signaling in ovarian cancer. Dependence of these core 
oncogenic pathways for cell proliferation and survival allows them to collaborate 
with genetic mutations in the same pathways, providing “addicted” growth 
advantages that pomote tumor development. Thus, genome-wide mapping genetic 
and epigenetic gene silencing might provide new insights into cancer prevention and 
therapy. 
Large-scale initiatives to map somatic mutations and gene expression have 
revealed a large number of genetic alterations that contribute to inactivation of tumor 
suppressor in cancer cells (Beroukhim et al., 2010; Ding et al., 2008; Kan et al., 
2010; Wood et al., 2007). In addition, epigenetic gene silencing due to DNA 
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methylation is one of the most common mechanisms for tumor suppressor genes to 
be inactivated during tumorgenesis (Baylin and Ohm, 2006). Recent efforts in 
genome-wide studies have also showed that epigenetic regulation of tumor 
suppressor genes is tightly linked to chromatin modifications, such as histone 
methylation and deacetylation (Esteller, 2008; Ohm et al., 2007). For example, 
transcriptionally active tumor suppressor genes are characterized by active chromatin 
marks, such as trimethylated histone H3 lysine 4 (Mikkelsen et al., 2007; Zhao et al., 
2007) . Thus, the restoration of H3K4me3 could be a useful marker for detecting the 
reactivation of silenced tumor suppressor genes after DNA demethylation treatment. 
Current technology advancements in high-resolution, genome-wide mapping of 
DNA methylation and histone modifications including ChIP-PET or ChIP-seq are 
widely utilized to characterize epigenome modifications during cancer development 
(Kondo et al., 2008; McGarvey et al., 2008; Meissner et al., 2008; Mikkelsen et al., 
2007; Zhao et al., 2007). The advancements in genome-wide technologies provide an 
excellent platform to carefully characterize and dissect the mechanisms behind 
epigenome dysregulation in cancer.  
In this chapter, a genome-wide approach was adopted to identify genes that are 
silenced by DNA methylation in colon cancer. Through integrated genomic and 
epigenomics analysis, A high-throughput strategy was utilized to identify the 
silenced genes in CRC. The workflow of this study is illustrated in Figure 3.1. Two 
well-defined isogenic HCT116 and DKO cell lines (HCT116 cells harboring genetic 
disruptions both DNMT1 and DNMT3B loci (DKO)) were used, Microarray 
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analysis was performed to compare the differentially regulated genes in HCT116 and 
DKO or HCT116 treated with DNA demethylation agent, 5-AzaC. Subsequently, 
hierarchical clustering was performed based on the mRNA expression levels of a 
panel of colon cancer cell lines along with 24 pairs of colon primary tumors matched 
with their respective normal colon musco. By overlapping these two sets of genes,  
a subset of DNA methylation-regulated genes were identified. In addition to above 
analysis, ChIP-seq analysis was performed to examine the H3K4me3 occupancy in 
HCT116 and HCT116-DKO to identify the active promoter regions of the tumor 
suppressor genes. Finally, genes with H3K4me3 marks in DKO cells but not in 
HCT116 cells were overlapped with the list of cancer related methylated genes to 
select as a group of colon cancer methylation silencing genes (CMS) for further 
study. In this study, we have demonstrated that the changes in H3K4me3 signature 
before and after removal of DNA methylation could lead to the identification of 
tumor suppressor genes that are epigenetically regulated during cancer progression. 
Functional analysis of randomly selected CMS genes have demonstrated that the 
re-expression of these genes could suppress tumorigenicity in colon cancer cells. 
These observations demonstrate that the integration of genomic and epigenomic 
studies is an efficient strategy to identify DNA methylated genes that are involoved 






Figure 3.1 Strategy of integrative genomic and epigenomics analysis used to 
identify DNA methylation targets in cancer. 
Transcriptional targets of DNA methylation repression were identified by expression 
profiling in HCT116 and DKO cells or HCT116 cells treated with DNMT inhibitor 
5-AzaC. This DNA methylation repression signature were evaluated for clinical 
relevance in CRC. In parallel, a cohort of gene promoters occupied by the H3K4 
tri-methylation was identified by genome-wide location analysis. The caner related 
DNA methylation genes that are also physically bound by the H3K4me3 in DKO only 







3.2 Results   
3.2.1 Microarray analysis reveals epigenetically silenced genes by 
DNA hypermethylation in colon cancer cell lines 
The purpose of this study is to characterize silenced genes by DNA methylation. To 
do this, we first carried out microarray analysis in colorectal cancer cell line HCT116 
and its counterpart HCT116-DKO in which both DNMT1 and DNMT3B are 
genetically disrupted or HCT116 cells treated with DNA methylation inhibitor 
5-aza-cytidine (Aza). Changes of mRNA expression in DKO and HCT116 with or 
without 5-AzaC treatment were analyzed using the Sentrix® HumanRef-8_V2 
Expression BeadChip Kit(Illumina, USA). Microarray scanned images were 
imported to Illumina® GenomeStudio 2010 for data quality control. With 
GeneSpring GX 11.0.2, the gene expression level data file were transformed to log2 
values and quantile normalized. With the normalized gene expression levels, 
significant genes were selected based on significance analysis of microarrays (SAM) 
by separately comparing HCT116-DKO or HCT116/5-AzaC with the HCT116 
parental control (HCT116). Genes with significant differential expression were 
selected based on a minimum 3 fold change and FDR (False Discovery Rate ) < 
0.1%. Using the Illumina BeadChip technology, we identified 1,275 genes with 
upregulated expression in either HCT116-DKO cells or HCT116 cells treated with 
5-aza-dC compared to HCT116 cells (Figure3.1A). Hierarchical clustering analysis 
revealed 753 genes that was consistently repressed across a panel of colon cancer 
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cell lines compared to normal colon epithelium (Figure3.1B). These data suggest that 
DNA methylation at these genes might be used extensively to repress their 





Figure 3.2 Genes silenced by DNA hypermethylation in colon cancer cancer cell 
lines. 
(A) 1275 genes were upregulated with 3 fold or greater in either DKO cells or 
HCT116 cells treated with 5.0 µM 5-AzaC for 3 days compared to parental 
HCT116 cells. 
(B) Expression profiles of 1275 genes in normal colon tissue and multiple colon 
cancer cell lines, and 753 genes show consistent downregulation in multiple colon 






3.2.2 Microarray analysis reveals silenced genes in primary colon 
tumors 
As aberrant DNA methylation plays a critical role in human cancer progression, we 
proceeded to source out for DNA methylation-suppressed genes with clinical 
relevance. To determine whether the above gene set identified in established cell 
lines are of clinical relevance, we carried out microarray analysis in colon primary 
tumor to compare their expression profiles. We subjected the 753 downregulated 
genes into the microarray database of 24 pairs of clinical colon tumor samples with 
matched normal colon tissues. The hierarchical clustering analysis revealed that 476 
out of 753 genes showed a consistent and marked repression in tumors compared to 
the matched normal controls, illustrating the clinical relevance of this subset of genes 
beyond the initial cell lines studied (Figure3.2). Among this 476 gene, some are 
well-established genes that were previously reported to be silenced by DNA 
hypermethylation in colon cancer, such as SFRP1, CDH2, and UCHL1 
(Okochi-Takada et al., 2006; Suzuki et al., 2004). 
70 
 
Figure 3.3 476 out of 753 genes show consistent downregulation in human 















3.2.3 Genome-wide mapping H3K4me3 marks in HCT116 and 
DKO cells 
Histone H3 lysine 4 trimethylation (H3K4me3) is considered to be a marker of an 
active gene promoter (Mikkelsen et al., 2008; Zhao et al., 2007), and the majority of 
these marks are located within 1.0 kb of transcription start site (TSS). Moreover, 
H3K4me3 and DNA hypermethylation are mutually exclusive: DNMTs only 
recognize sites with unmethylated H3K4 (Ooi et al., 2007; Weber et al., 2007) and 
loss or gain of H3K4 methylation is a strong predictor of promoter DNA methylation 
status (Meissner et al., 2008). As such, by investigating the H3K4me3 status in our 
original HCT116 cells and the corresponding DNMTs double knock out line (DKO 
cells) would provide a measure of promoter activity (and DNA methylation status) 
that is independent of our gene expression profiling. Using genome-wide microarray 
analysis, we uncovered 476 genes consistently silenced in both colon cancer cell 
lines and primary tumors, which were thus associated with clinical relevance. We 
next examined the H3K4me3 signature of these 476 genes in HCT116 cells and its 
counterpart HCT116-DKO cells. We performed chromatin immunoprecipitation 
(ChIP) using antibodies against H3K4me3 in both HCT116 and DKO cells followed 
by high-throughput sequencing analysis. Thus a genome-wide map of H3K4me3 
binding sites in both HCT116 and DKO cells were generated. A total of 11,747 and 
13,074 high confidence H3K4me3 sites were identified in HCT116 and DKO cells, 
respectively, within 1.0 kb of a TSS (using a false discovery rate [FDR] of 0.1%). 
Overlapping these two data sets revealed 2,507 gene promoters that lacked 
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H3K4me3 in HCT116 cells but gained this mark in the DKO cells (Figure 3.4).We 
designated this group of genes as DNA methylation targets, which could be 
reactivated by DNA demethylation in DKO cells but silenced in HCT116 cells. 
 
 
Figure 3.4 Genome-wide analysis of H3K4me3 was done in HCT116 and DKO 
cells by using ChIP-seq and Solexa Genome Analyzer. 
Venn diagram depicts the overlapping of gene promoters marked by H3K4me3 
surrounding the transcriptional start site (<1.0 kb) from the two cell lines. 10567 
promoters were binded by H3K4me3 as expressed genes in both HCT116 and DKO 
cells. 1180 promoters were identified as gain of H3K4me3 in HCT116 cells. 2507 


















3.2.4 Identification of cancer methylation silenced genes (CMS) 
To distinguish the most robust gene set that appeared to be silenced in colon cancer 
cells by DNA methylation, we next identified the genes that fell in the union 
between those genes identified by expression Beadchips and those by H3K4me3 
ChIP-seq. By comparing with above-identified 476 DNA methylation silenced genes 
with 2507 H3K4me3 marks in DKO cells but not in HCT116 cells, we were able to 
identify a set of 203 genes that appears to be truly silenced by DNA methylation and 
lack of detectable H3K4me3 in HCT116 cells and they are re-expressed in DKO 
cells with a gain of H3K4me3 (Figure 3.5). For convenience of the description in the 
following studies, we define these genes as colon cancer methylation silenced genes 
(CMS) in the remaining of the chapter. 
 
 
Figure 3.5 203 silenced genes by DNA methylation 
Venn diagram depicting an overlap of 203 genes that were repressed by DNA hypermethylation 




3.2.5 Validation of cancer methylation silenced genes (CMS) 
To examine whether the CMS genes were indeed silenced by DNA methylation in 
HCT116 cells and reactivated in DKO cells by DNA demethylation and H3K4 
tri-methylation. Two well-known genes silenced by DNA methylation were selected 
for validation.  Two CMS genes (SFRP1 and CDH2) illustrated in Figure 3.6 
exemplify such changes in DNA methylation and H3K4me3 in HCT116 and DKO 
cells. RT-PCR results indicated that both SFRP1 and CDH2 were reactivated in DKO 
cell but not in HCT116 cells (Figure 3.6A). Methylation-specific PCR (MSP) was 
performed to check the DNA methylation status in the promoter. As shown in Figure 
3.6B, both SFRP1 and CDH2 were hypermethylated in HCT116 cells, which only 
amplified by methylated-primer (M) but not by unmethylated-primer (U). In contrast, 
bisulfite DNA was only amplified by unmethylated primer in DKO cells, which 
indicate DNA promoter was demethylated in DKO cells. At the same time, ChIP-seq 
data shows that H3K4me3 was only bound on the active promoter of DKO cells but 
not HCT116 cells (Figure 3.6C). We further examined an additional set of randomly 
selected CMS genes by RT-PCR and methylation-specific PCR (MSP) (Figure3.7A 
and 7B). In each case, the gene was verified to be promoter methylated and silenced 
in HCT116 cells but became demethylated and re-expressed in DKO cells, validating 





Figure 3.6 Representative genes showing the differential gene expression, 
methylation status and H3K4me3 in HCT116 and DKO cells. 
(A) RT-PCR shows that SFRP1 and CDH2 were silenced in HCT116 and  
re-expressed in DKO cells. 
(B) MSP shows that SFRP1 and CDH2 promoters were methylated in HCT116 cells 
but demethylated in DKO cells. 
(C) ChIP-seq result shows that H3K4me3 was detected at SFRP1 and CDH2 
promoters in DKO cells but not in HCT116 cells. 
 
Figure 3.7 Validation of CMS genes in HCT116 and DKO cells. 
(A) RT-PCR analysis of random-selected CMS genes in HCT116 and DKO cells. 
(B) MSP analysis of the CMS genes as (A) in HCT116 and DKO cells. M, 




3.2.6 A global analysis of CMS genes reveals pathways 
dysregulated in CRC 
A pathway analysis revealed that a number of DNA methylation targets were 
implicated in pathways which have important roles in regulating tumorigenesis 
(Sjoblom et al., 2006; Wood et al., 2007), and the silencing of these CMS genes 
would lead to induction of these pathways (Figure3.8). For example, epigenetic 
repression of extracellular Wnt inhibitors, such as DKK1/3 and SFRP1, has been 
often reported in human colorectal cancer cells (Baylin and Ohm, 2006), which lead 
to aberrant Wnt/b-catenin signaling in colorectal cancer cells. To identify novel 
signaling pathways involved in the loss of CMS genes, we performed an Ingenuity 
Pathway Analysis using the 203 CMS genes and mapped the pathways onto the 
heatmap of colon primary tumors. Table 3.1 shows the results of Gene Expression 
Ontology (GEO) analysis of the top function of CMS genes. These results indicated 
that many of these CMS genes are involved in cell movement, cell death, and cell 
proliferation, which were ranked by p-value. Figure 3.8 shows that loss of CMS genes 
results in activation of known oncogenic pathways in CRC according to the IPA 
results. The loss of the DNA methylation targets such as RASD1 and DDIT4L leads to 
the activation of RAS and PI3K/mTOR pathway, respectively. In addition to these 
WNT inhibitors like SFRP1 and DKK1, WNT5B and SRY-box containing gene 
17(SOX17) were also identified as tumor suppressor genes silenced by DNA 
methylation, which targets the WNT signaling pathway (Zhang et al., 2008). Among 
these inhibitors of oncogenic pathways, some are important transcription factors that 
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were shown to contribute to the regulation of neoplastic process. For example, 
HAND1 works as a differentiation transcription factor and functions as a tumor 
suppressor in melanoma and thoriod carcinomas (Martinez Hoyos et al., 2009; Tellez 
et al., 2009), which is also silenced by DNA methylation. Taken together, these 
results suggest that DNA methylation plays as a pivotal mechanism in the loss of 
CMS genes, and such loss of CMS genes may contribute to activation of oncogenic 
signaling in colorectal cancer. 
. 
Table 3.1 The top10 list of GEO results of 203 CMS genes. 
  Category  p-value 
1  Cellular Movement 3.55E-08-9.56E-03 
2  Genetic Disorder 1.12E-07-9.56E-03 
3  Cell Death 3.47E-07-9.56E-03 
4  Cellular Growth and Proliferation 1.1E-06-8.94E-03 
5  Tissue Development 1.67E-06-9.56E-03 
6  Cancer 2.46E-06-9.56E-03 
7  Reproductive System Disease 2.83E-06-9.56E-03 
8  Nutritional Disease 5.23E-06-9.56E-03 
9  Cell Signaling 5.93E-06-5.25E-03 




Figure 3.8 Potential oncogenic signaling pathways in colorectal cancer 
Potential oncogenic signaling pathways that were involved in the inactivation of tumor 
suppressor functions of the 203 CMS genes. 
 
3.2.7 Functional validation of CMS genes in colon cancer cells 
A subset of CMS genes were previously reported as tumor suppressors in CRC. 
However, the function of the unknown CMS genes remain elusive. To investigate the 
tumor suppressive potentials of CMS genes in colon cancer cells, we constructed 
expression vectors encoding various CMS genes of interest and carried out colony 
formation assays in cancer cell lines. We focus on three CMS genes (RASD1, 
HAND1, and THY1) and their ability to function as suppressors of tumor growth in 
HCT116 and DLD1, in which all three genes were silenced. We tested these three 
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genes by a colony formation assay in soft agar using zeocin selection after 
transfection with each gene or control vector (pcDNA4). Figure3.9 showed that the 
restoration of HAND1, RASD1 and THY1 genes in both DLD1 and HCT116 cells 
significantly reduced the colony formation ability in soft-agar assay, which indicated 
that all three genes have potent tumor-suppressing activity. In generally, these results 
suggest that re-expression of the CMS genes may suppress the cancer phenotype in 
colon cancer cells. 
 
Figure 3.9 Anchorage-independent colony formation assay in soft-agar 
Human full-length RASD1, HAND1 and THY1 were cloned in pcDNA4 
mammalian expression vector and transfected into both DLD1 and HCT116 cells. 
transfected cells were seeded for colony formation assay in soft-agar. Representative 
















In this chapter, we used two complementary approaches to harness the power 
of comprehensive profiling technologies for the identification and validation of 
silensing tumor suppressor genes in colorectal cancer. Through integrative genomic 
and epigenomic analysis, we identified 203 novel DNA methylation silencing genes 
and many of them have been implicated in human malignancies. For example, WNT 
signaling inhibitors, such as SFRP1, WNT5B, and SOX17, were identified by 
screening for epigenetically silenced genes in CRC cells, and their methylation was 
subsequently found in colon primary tumors (Suzuki et al., 2004; Zhang et al., 2008). 
Epigenetic silencing of these WNT signaling antagonists may collaborate with 
genetic alterations of β-catenin or APC and contribute to the abnormal activation of 
WNT signaling pathway in CRC (Baylin and Ohm, 2006). The high frequency of 
DNA methylation of these tumor suppressor genes in CRC is suggestive of their 
tumor suppressor function. Functional studies of several CMS genes showed that 
these CMS genes work as tumor suppressors in colon cancer cells. Moreover, a 
significant number of CMS genes have also been reported to be silenced by DNA 
hypermethylation in other cancers, such as ADRB2, THY1 and RASD1, which 
function as tumor suppressors in prostate cancer, nasopharyngeal carcinoma and 
other cancers (Lung et al., 2005; Yu et al., 2007).  
Cancer progression is associated with poor differentiation of cancer cells. A 
link between DNA methylation event in cancer and differentiation program has not 
been demonstrated. In this study, we have identified a differentiation transcription 
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factor HAND1 that was silenced by DNA methylation in colon cancer and showed 
that restoration of HAND1 is able to inhibit colony formation in soft agar. Given that 
the silencing of HAND1 occurred in near 90% of colon cancer, we predict that loss 
of this gene is an important developmental regulator in colon tissue and might play 
an important role in cancer progression. Moreover, the high frequency of DNA 
methylation-mediated silencing of HAND1 indicates that it could be a novel tumor 
marker for early detection of colorectal cancer. Among the 203 CMS genes, some of 
them encode protein phosphatases, such as PPP1R3C, PPP1R16B and PP2A B 
subunit PPP2R2B. Given the importance of protein phosphatases in regulating 
various kinases in oncogenic pathways, we selected the PP2A B subunits PPP2R2B 
for further functional study which will be discussed in detail in the chapter IV.  
In summary, we provide compelling evidence that a large number of DNA 
methylation genes are extensively silenced by DNA methylation and are strikingly 
deficient of active histone modification H3K4 tri-methylation in the DNA promoter 
in CRC. Our data suggest that DNA demethylation can alter the H3K4me3 signature 
of numerous silenced tumor suppressor genes in cancer, and that re-expression of 
these genes has important relevance to the effects of epigenetic related cancer 













4 Chapter IV: Functional investigation of PPP2R2B 













4.1 Introduction  
Protein phosphatase 2A (PP2A) belongs to a family of holoenzyme complexes 
that function in various cellular signaling pathways (Eichhorn et al., 2009; Janssens 
et al., 2005; Westermarck and Hahn, 2008; Yeh et al., 2004). PP2A dephosphorylates 
various protein kinases which are involved in multiple oncogenic signaling pathways. 
Thus, PP2A often functions as a tumor suppressor in human cancer (Mumby, 2007). 
Mechnistically, PP2A works as a multimeric enzyme that contains the catalytic C 
subunit, a scaffolding A subunit and one of regulatory B subunits. In mammals, both 
catalytic C and structural A subnit have α and β isoforms. On the other hand, there 
are four B subunit families, each with several isoforms or splice variants (Virshup 
and Shenolikar, 2009). Therefore, variability in the PP2A holoenzyme composition 
results in the substrate specificity and catalyzes distinct dephosphorylation events 
imposing different functional outcomes. 
Loss-of-function for tumor suppressors leads to cancer due to uncontrolled cell 
growth and affects the initiation and progression of cancer (Blume-Jensen and 
Hunter, 2001; Futreal et al., 2004; Stratton et al., 2009). Inactivation of tumor 
suppressor genes can result from both genetic mechanisms such as mutation and 
deletion or epigenetic mechanisms such as DNA methylation and histone 
modification (Baylin and Ohm, 2006; Esteller et al., 2001; Ponder, 2001). 
Identification of these genes provides insights into the biological processes and 
pathways underlying tumorigenesis. Although the tumor suppressor role of PP2A has 
well-established in numerous immortalized human cell lines of different tissue orgins 
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(Chen et al., 2004; Hahn et al., 1999), the genetic and/or the epigenetic evidence 
pointing to a PP2A inactivation in human malignancy are largely unexplored. A few 
studies have shown that somatic mutations in the A subunit of PP2A complex, which 
led to the loss of B subunit binding, was found to be present in only 15% of lung, 
breast, and colon cancer (Sablina et al., 2007; Wang et al., 1998), while another 
study showed that a specific PP2A complex containing B56γ subunit is 
down-regulated in lung cancer (Chen et al., 2004). Overall, very little is known about 
how PP2A complexes are altered in human cancer, as well as their effects on cancer 
signaling pathways and related therapeutic response. 
In chapter three, we discovered a set of colon cancer methylation silenced 
(CMS) genes in human colorectal cancers through integrative genomic and 
epignomic analysis. Among of these CMS genes, We identified a specific PP2A 
regulatory B subunit, PPP2R2B that was silenced by DNA hypermethylation in 
human colorectal cancer. In this chapter, we first examined the mRNA expression 
profiles of all subunits of PP2A in colon cancer cell lines and colon primary tumors 
to evaluate whether PPP2R2B is the only suppressed subunit of PP2A complexes. 
We hypothesized that PPP2R2B-associated PP2A complexes might have a functional 
role in regulating cancer cell proliferation. Thus, the aim of this project is to identify 
the underlying mechanism behind the silencing of PPP2R2B in colorectal 
cancer(CRC). Most importantly, we will define the biological functions of this 
specific PPP2R2B-associated PP2A complex and investigate the signaling pathways 
that are affected by this complex in colon cancer. Furthermore, we hope to identify 
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the target substreates which could be dephosphorylated upon restoration of 
PP2A-PPP2R2B complex in CRC. 
4.2 Results   
4.2.1 Loss of PPP2R2B expression in colorectal cancer 
PPP2R2B is the only PP2A B subunits silenced in CRC lines 
Given the low frequency of mutations found in PP2A family members in human 
malignancy, including colorectal cancer(CRC), we sought to determine whether they 
are epigenetically inactivated in CRC. In the previous studies, PPP2R2B was 
identified to be epigenetically silenced by DNA hypermethylation (one of 203 CMS 
genes) in colon cancer cells. To address the role of epigenetic silencing of PPP2R2B, 
the expression profiles of all PP2A subunits was first determined using the Illumina 
Beadchip gene expression array (Human Ref-8_V2). In a panel of colorectal cancer 
cell lines and one normal colon mucosa examined, PPP2R2B gene that encodes for  
B55β is the only subunit that is consistently downregulated or silenced in all 
examined CRC cell lines, but not in the normal colon mucosa samples (Fig4.1A and 
Table4.1). This finding was subsequently validated by semiquantitative RT-PCR 
using primers specifically targeting PPP2R2B in a panel of CRC cell lines and 
normal colon tissues. The RT-PCR results showed that PPP2R2B was expressed in 
the normal colon tissues but silenced in all the CRC cell lines (Fig4.1B). In contrast, 
PPP2R2A (B55α) and PPP2R5C (B56γ), which has been previously reported to be 
downregulated in lung cancer (Chen et al., 2004), were not downregulated in CRC. 
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Taken together, these results demonstrated that the loss of PPP2R2B was observed 
across all CRC cell lines as compared to normal colon tissue. 
 
Figure 4.1 PPP2R2B gene is suppressed in CRC cell lines but not in normal 
colon tissue 
(A) Hierarchical clustering of PP2A subunits in human colorectal cancer cell lines. 
(B) RT-PCR analysis of PPP2R2B expression in colon cancer cell lines and normal 
colon tissues. 






PPP2R2B is frequently silenced in colorectal primary tumors and other human 
malignancies 
To identify the clinical evidence linking PPP2R2B expression in colon cancer, the 
PPP2R2B expression was examined in 24 pairs of colon primary tumors and 
matched normal controls using box-plot analysis. The data showed that PPP2R2B 
was significantly downregulated in patient-derived CRC tumors compared to 
matched normal mucosa controls (p < 0.001, Figure 4.2A). Moreover, the loss of 
PPP2R2B appeared to occur in more than 90% of CRC samples when we clustered 
all the PP2A subunits in the 24 pairs of CRC tumors and matched normal samples 
(Figure 4.2B). The downregulation of PPP2R2B in colon primary tumors was further 
verified by perfoming RT-PCR on randomly-selected colon tumor samples and their 
matched normal adjacent tissues (Figure4.2C). In contrast, PPP2R2A and PPP2R5C 
were not downregulated in CRC. These data demonstrated that PPP2R2B is the only 
silenced subunit of PP2A complex in colon cancer and the downregulation of 
PPP2R2B expression has highlighted a crucial role of PPP2R2B in colon cancer 
development. In addition, the data mining in the oncomine database revealed that 
PPP2R2B is downregulated in a variety of other human tumors including bladder, 
brain and esophagus cancer, indicating its frequent inactivation in human 
malignancy (Figure 4.3). Thus, these results from cancer cell lines and clinical data 







Figure 4.2 PPP2R2B gene is suppressed in colon tumor. 
(A) Box-plot showing the differential expression of PPP2R2B mRNA levels in 24 
pairs of patient-derived CRC and matched normal colon mucosa as determined by 
Illumina array analysis. P value for difference between tumor and normal is 
indicated. 
(B) Hierarchical clustering of all PP2A subunits in human colorectal tumors (T) and 
matched normal mucosa (N).  
(C) RT-PCR analysis of PPP2R2B expression from eight randomly selected pairs of 







Figure 4.3 PPP2R2B is downregulated in human cancers 
Box-plots showing the differential expression of PPP2R2B mRNA in tumor and 
corresponding normal tissues of bladder (Dyrskjot et al., 2004; Sanchez-Carbayo et al., 
2006), brain (Rickman et al., 2001; Shai et al., 2003; Sun et al., 2006), esophagus 
(Wang et al., 2006) and colon (Ki et al., 2007). Representative data were shown 
across several independent published microarray studies from the ONCOMINE 
website. The y-axis represents normalized expression and the p-values for correlation 







4.2.2 PPP2R2B is silenced by DNA hypermethylation 
PPP2R2B is silenced by DNA methylation in CRC 
It is well established that aberrant CpG methylation in the DNA promoter is related 
to gene silencing in cancer development. We next determined whether the loss of 
PPP2R2B expression in CRC is associated with promoter DNA hypermethylation. In 
order to identify the silencing mechanism of PPP2R2B, methylation-specific PCR 
(MSP) was used to survey the methylation status of PPP2R2B promoter in primary 
tumor samples. A predicted CpG island was identified in the immediate upstream of 
the genomic region of PPP2R2B gene by using bioinformatics analysis (Figure 
4.5C). MSP primers were designed in the CpG island of promoter region according 
to the bisulfite DNA sequence, which designated with M (Methylated primer) and U 
(Unmethylated primer). MSP was performed by using methylated primers or 
unmethylated primers, respectively. MSP results showed that PPP2R2B was found 
methylated in all 8 primary tumors but unmethylated in matched control normal 
colon tissue (Figure 4.4A). Similar with the primary tumor samples, we also 
analyzed the the methylation status of PPP2R2B in a panel of colon cancer cell lines 
and non-transformed epithelial cells. MSP results showed that cell lines with 
silenced expression had methylated promoters compared to normal colon tissue 
(Figure 4.4B). No methylation was detected in non-transformed epithelial cells 
(Figure 4.4C). These data support the notion that PPP2R2B methylation was 






Figure 4.4 PPP2R2B was silenced by DNA promoter hypermethylation in colon 
cancer. 
(A) MSP analysis of PPP2R2B promoter in eight selected tumors and matched 
normal mucosa.  
(B) Methylation status of PPP2R2B in colorectal cancer cell lines and normal colon 
tissue.  
















PPP2R2B is reactivated by demethylation in the promoter  
DNA promoter methylation is mediatated by DNA methyltransferases (DMNTs), 
such as DNMT1 and DNMT3B (Okano et al., 1999). In recent years, many reports 
have shown that pharmacologic or genetic disruption of DNA methylation in cancer 
cell induces upregulation of a substantial number of tumor suppressor genes 
(Herman and Baylin, 2003; Jones and Baylin, 2007). Indeed, colon cancer cell line 
HCT116 with the DNA methyltranferase genes DNMT1 and DNMT3B depletion 
(DKO cells) showed a re-expression of PPP2R2B (Figure 4.5A left). Similarly, 
DLD1 cells treated with DNMT inhibitor 5-aza-dC resulted in an increase in 
PPP2R2B expression (Figure 4.5A right). In agreement with the restoration of 
PPP2R2B expression in DKO cells, MSP results indicated the demethylation of the 
promoter in DKO cells compared to the hypermethylated promoter in HCT116 cells 
(Figure4.5B). The detailed methylation status of individual CpG sites in the 
promoter was further examined by bisulfite genomic sequencing (BGS) analysis in 
normal colon tissue and HCT116 or DKO cells. The results were consistent with 
those of MSP (Figure4.5C) indicating that an epigenetic-mediated silencing of 












Figure 4.5 PPP2R2B is reactivated by demethylation in DNA promoter 
 (A) RT-PCR analysis of PPP2R2B in HCT116 and DKO or DLD1 cells treated 
with or without 5-AzaC (5 µM) for 3 days. 
(B) MSP analysis of PPP2R2B promoter in HCT116 and DKO cells. M: methylated; 
U: unmethylated. 
(C) Methylation analysis of PPP2R2B promoter by bisulfite-sequencing analysis 
(BGS). The region analyzed is indicated. The arrow indicates the transcriptional start 






4.2.3 PPP2R2B functions as a tumor suppressor in CRC 
PPP2R2B restoration in colon cancer cells inhibits colony formation 
Loss of PPP2R2B expression may impair the tumor suppressor activity of PP2A in 
colon cancers. This hypothesis predicts that cells with defective PPP2R2B function 
may be sensitive to the reconstitution of PP2A complex by exogenous re-expression 
of PPP2R2B. To investigate the tumor suppressor properties of PPP2R2B, we 
examined this possibility by ectopically expressing PPP2R2B with a mammalian 
expression vector in two colon cancer cell lines that do not express PPP2R2B 
(DLD1 and HCT116). Subsequently, functional assays was conducted to detect 
phenotypic changes in cell viability and anchorage-independent growth. Ectopic 
expression of PPP2R2B inhibits colony formation in both HCT116 and DLD1 cells 
(Figure4.6A). The strong growth inhibitory effect of PPP2R2B was further 
substantiated in two additional CRC cell lines by using retroviral transduction of 
both GFP and PPP2R2Bs, which led to an inhibition of growth in soft agar. As 
shown in Figure 4.6B, restoration of PP2A-PPP2R2B complex significantly reduced 
anchorage-independent growth rate in both SW480 and HT29. These results 
indicated that ectopic expression of PPP2R2B inhibits colony formation in CRC 
cells.  
Establishment of Tet-on inducible expression cell system 
To further elucidate the function of PPP2R2B as a potential tumor suppressor, we 
generated a Dox-inducible expression system in both DLD1 and HCT116 cells 
expressing either the wild-type PPP2R2B or empty vector as negative control. A 
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brief workflow of Tet-on inducible expression system was shown in Figure 4.7A. 
After selection by using blasticidin and zeocin antibiotics, single clones were picked 
up and amplified for screening by immunoblotting analysis of PPP2R2B with Myc 
tagged anti-Myc antibody (9E10). As shown in Figure 4.7B, two clones with lowest 
background and strongest induction by doxycycline were seleted for functional 
















Figure 4.6 Restoration of PPP2R2B in colon cancer cells inhibits cell 
proliferation and anchorage-independent growth. 
(A) Foci formation assay in DLD1 and HCT116 cells with transient expression of 
PPP2R2B and empty vector. 1x104 cells were seeded in 6 well plate and selected 
with 100µg/ml Zeocin for 14 days.  
(B) Anchorage-independent growth assessed by soft agar assay in SW480 and HT29 
cells infected with retroviral PPP2R2B expression vector. GFP positive cells were 




Figure 4.7 Generation of Tet-on inducible expression cell system 
Figure 4.7 Generation of Tet-on inducible expression cell system 
(A) Workflow of construction of Tet-on inducible expression cell system. 
(B) Representative immunoblotting analysis of screening for stable clones with 







Gain-of-function analysis of PPP2R2B in inducible cell system in vitro 
To further evaluate the tumor suppressor effects of PPP2R2B, we established stable 
DLD1 and HCT116 cell lines with doxycycline inducible expression of a 
Myc-tagged PPP2R2B, designated as DLD1-PPP2R2B or HCT116-PPP2R2B. As 
shown in DLD1-PPP2R2B cells, addition of Dox resulted in PPP2R2B-Myc 
(B55β-Myc) expression at levels comparable to the endogenous expression of other 
three B55 subunits that were not silenced in DLD1 cells, using an antibody that 
recognizes a total four B55 subunits (α, β, γ, and δ)(Figure 4.8A). The results show 
that B55β-Myc is induced in CRC cells at a physiological level. Under this condition, 
ectopic expression of PPP2R2B resulted in a typical senescence phenotype, 
including enlarged and flattened cell morphology, as well as increased 
senescence-associated β-galactosidase (SA-β-Gal) (Figure 4.8B). Accordingly, DNA 
synthesis as measured by BrdU incorporation decreased markedly after PPP2R2B 
re-expression by doxycycline treatment(Figure 4.8C), indicative of inhibition of cell 
proliferation. Furthermore, colony formation assay in soft-agar was performed in 
both HCT116 and DLD1 inducible cell system in the presence or absence of 
doxycycline. The results showed that PPP2R2B restoration caused a strong 
inhibition of anchorage-independent growth in both HCT116- and DLD1-PPP2R2B 
cells compared to the control vector cells(Figure 4.8D). Taken together, these results 






Figure 4.8 Restoration of PPP2R2B results in senescence, decreased cell 
proliferation and strong inhibition of anchorage-independent growth 
(A) Immunoblot analysis of DLD1-PPP2R2B cells on exogenous B55β and 
endogenous B55 using anti-Myc tag or anti-B55 subunit antibody. Cells were treated 
with or without 10 ng /ml doxycycline for 3 days. 
(B) SA-β-gal assay of DLD1-PPP2R2B or vector control cells treated with or without 
Dox for 96 hr. Scale bars, 100 µm. 
(C) BrdU incorporation of DLD1-PPP2R2B or vector control cells treated with or 
without Dox for 96 hr. Shown is mean ± SD of three independent experiments. 
**p < 0.001. 
(D) Anchorage-independent growth assessed by soft agar assay in DLD1-PPP2R2B 










PPP2R2B re-expression blocks tumorigenicity in vivo 
After demonstrating that PPP2R2B could function as a tumor supressor of colon 
cancer cell lines in vitro, the capacity of PPP2R2B in tumor growth inhibition in vivo 
was subsequently assessed. Dox-inducible DLD1 cells expressing PPP2R2B or the 
empty vector were subcutaneously injected into nude mice and tumor growth was 
monitored for 3 weeks with or without daily Dox administration. The data showed 
that the tumor growth derived from DLD1-PPP2R2B cells was markedly inhibited in 
mice treated with Dox, whereas the tumor growth from the DLD1 cells expressing 
the control vector was slightly unaffected by Dox treatment (Figure 4.9). The result 
confirmed the growth inhibitory activity of PPP2R2B in the xenograft mouse model. 
Taken together, our in vitro and in vivo assays indicate that PPP2R2B works as a 
tumor suppressor in CRC. 
 
Figure 4.9 Restroration of PPP2R2B in DLD1 cells inhibits tumorigencity in 
xenograft mouse model 
Xenograft tumor growth of DLD1-PPP2R2B or control cells in nude mice treated 
with Dox at 100 mg/kg daily. Error bars represent mean ± SD (n = 8 per group). **p 
< 0.01 (independent t test). 
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4.2.4 PPP2R2B knockdown promotes cell transformation 
We next addressed whether ablation of PPP2R2B is sufficient to promote cell 
transformation in human embryonic kidney fibroblasts, in which SV40 large antigen 
(LT), hTERT and oncogenic H-RAS (HEK-TERV) are expressed to immortalize but 
not sufficient to induce tumorigenicity (Chen et al., 2004). In this previously 
well-characterized transformation model, inhibition of PP2A by overexpression of 
small T antigen (ST) results in efficient transformation (Chen et al., 2004; Hahn et al., 
2002; Sontag et al., 1993). Small interfering RNAs (siRNA) targeting different 
regions of PPP2R2B were transfected into HEK-TERV cells and harvested for qPCR 
to evaluate the efficiency of siRNA-mediated gene silencing (Figure 4.10A). As 
shown in Figure 4.10B, siRNA-directed knockdown resulted in an enormous increase 
in anchorage-independent growth of HEK-TERV cells compared to the control cells 
transfected with non-targeting siRNA(NC). ST was introduced into HEK-TERV cells 
as positive control for cellular transformation (Figure 4.10B). To further confirm the 
results of PPP2R2B knockdown, a retroviral shRNA vector pSIREN-zGreen targeting 
PPP2R2B was stably expressed in HEKT-TERV cells and a similar result was also 
obtained in HEK-TERV cells expressing a stable shRNA targeting PPP2R2B 
compared to non-targeting shNC(Figure 4.10C). On the basis of both the gain- and 








Figure 4.10 PPP2R2B knockdown in epithelial cells promotes cellular 
transformation 
(A) HEK-TERV cells were transfected with a PPP2R2B smart pool siRNA or an 
independent PPP2R2B siRNA and the PPP2R2B mRNA was assessed by TaqMan 
assay  
(B) Colony formation capacity was assessed by soft-agar assay. Shown on the left is 
quantification of number of colonies after 14 days from three independent 
experiments. The representative images of three independent experiments are shown 
on the right. SV40 small antigen (ST) expressing HEK-TERV cells were used as 
positive control. Scale bar, 10 µm. Error bar shows mean ± SD of triplicates. 
(C) HEK-TERV cells were infected with a PPP2R2B shRNA and negative control 
shRNA and the PPP2R2B mRNA was assessed by qRT-PCR (left panel). The error 
bar shows the mean ± SD of triplicates. Numbers of colonies are presented as the 
mean ± S.D. of three independent experiments (middle). Representative microscopy 







4.2.5 PPP2R2B-associated PP2A complex modulates 
phosphorylation of c-Myc and p70S6K in colon cancer cells. 
Oncogenic signaling pathways affected by PPP2R2B re-expression in CRC 
The PP2A B regulatory subunits determine the substrate specificity towards the 
dephosphorylation events in a cell and context-dependent manner (Virshup and 
Shenolikar, 2009). Several oncogenic proteins, including AKT, S6K and Myc, have 
been identified as the substrates of PP2A in various cell systems (Arnold and Sears, 
2008; Yeh et al., 2004). To identify the potential oncogenic events in colon cancer 
cells affected by PPP2R2B re-expression which leads to the growth inhibition, we 
probed the molecular changes in several known oncogenic pathways in 
HCT116-PPP2R2B cells treated with or without Dox for 48 hrs (Figure 4.11). Two 
phosphorylation events were found to be inhibited following PPP2R2B 
re-expression by Dox treatment, which were p70S6K T421/S424 and Myc. P70S6K 
T421/S424 was dephosphorylated while mTORC1-induced S6K T389 
phosphorylation was not affected upon PPP2R2B re-expression, suggesting a 
site-specific modulation of p70S6K by PPP2R2B. The second event is Myc 
phosphorylation, which is also inhibited by PPP2R2B re-expression in HCT116 cells. 
The other examined oncogenic signals, such as p-AKT, p-ERK, β-catenin and p-p38 
were not affected by PPP2R2B re-expression (Figure4.11), which suggests the 







Figure 4.11 PP2A-PPP2R2B complex inhibits p70S6K and Myc 
phosphorylation 
Ectopic expression of PPP2R2B in HCT116 inducible cells blocks p70S6K 








Restoration of PPP2R2B complex activity abolishes p70S6K and Myc 
phosphorylation in a time dependent manner 
The effects of PPP2R2B on p70S6K and c-Myc (thereafter referred to as Myc) 
were further confirmed in DLD1 cells in a time-course analysis (Figure 4.13A). The 
data showed that Dox induction of PPP2R2B expression resulted in a rapid 
dephosphorylation of Myc and p70S6K (T421/S424, but not T389) relative to total 
p70S6K and Myc protein levels, suggesting that these changes are the early effects 
of PPP2R2B and unlikely to be the secondary effect of growth inhibition. The 
decreased Myc phosphorylation eventually resulted in a lower level of total Myc 
protein after 48 hr of Dox treatment (Figure 4.13B), which is consistent with the 
previous finding that increased Myc phosphorylation at S62 correlates with Myc 
protein accumulation (Arnold and Sears, 2006; Junttila et al., 2007; Yeh et al., 2004). 
Thus, p70S6K and Myc are two downstream signals affected by PPP2R2B-PP2A 
complex, whereas no marked differences were observed in the expression levels nor 
phosphorylation status of other oncogenic signaling pathways known to be important 
in colorectal cancer.  
Of note, PPP2R2B re-expression neither effected AKT T308 phosphorylation 
(Figure 4.11), which known to be targeted by PP2A/B55α or B56β complex in NIH 
3T3 cells (Kuo et al., 2008; Padmanabhan et al., 2009), nor β-catenin 
phosphorylation is a target of PP2Aα in CRC (Su et al., 2008). In previous reports, 
SV40 small t antigen(ST)-mediated PP2A inhibition is associated with increased 
AKT S473 phosphorylation and the mTOR-mediated p70S6K T389 phosphorylation 
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in human mammary epithelial cell cells (Andrabi et al., 2007; Chen et al., 2005; 
Zhao et al., 2003), but these changes were not observed in this cellular context. 
These findings are consistent with the substrate specific functions of different 
PP2A/B subunits in various tissue specific contexts and show that 
PPP2R2B-associated PP2A complex is distinct from the other PP2A complexes by 
















Figure 4.12 PPP2R2B re-expression blocks S6K and Myc phosphorylation, as 
well as Myc accumulation in DLD1 inducible cells 
(A) Immunoblot analysis of DLD1-PPP2R2B or the vector control cells treated with 
or without Dox for the indicated length of times. 
(B) Immunoblot analysis of DLD1-PPP2R2B or the vector control cells treated with 











PPP2R2B binds to PP2A A and C subunit to form an active PP2A complex 
Functional PP2A complex is composed of the structural A and catalytic C subunit, and 
a regulatory B subunit. PPP2R2B is a B regulatory subunit of PP2A, which forms an 
active PP2A complex with A and C subunits to mediate its tumor suppressor function. 
To demonstrate that re-expression of PPP2R2B leads to the formation of the active 
PP2A complex with other subunits, Co-immunoprecipitation assays was performed 
using Myc antibody to pull down the PPP2R2B-Myc fusion protein and its binding 
partners. Immunoblotting analysis of the immunoprecipitates shows that the ectopic 
expression of PPP2R2B co-immunoprecipitated with both PP2A structural (A) and 
catalytic (C) subunits to form a complex (Figure 4.13A). Furthermore, in an in vitro 
PP2A phosphorylation activity assay using a synthetic phosphothreonine peptide 
RRA(pT)VA as the substrate (Chen et al., 2004), the immunoprecipitates of PPP2R2B 
from Dox-treated DLD1-PPP2R2B cells clearly displayed increased PP2A 
phosphatase activity compared to untreated DLD1-PPP2R2B or Dox-treated vector 
control cells (Figure 4.13B), suggesting that PPP2R2B re-expression restored the 












Figure 4.13 PPP2R2B binds to PP2A A and C subunits to form functional PP2A 
complex 
 (A) Coimmunoprecipitation of PP2A scaffolding A subunit and catalytic C subunit 
with PPP2R2B. DLD1-PPP2R2B or vector control cells were treated with Dox and 
PPP2R2B was immunoprecipitated with anti-Myc tag antibody. WCL, whole cell 
lysates. 
(B) Serine/threonine phosphatase activity for DLD1-PPP2R2B or vector control cells. 
Protein phosphatase activity of the immunoprecipitates of PPP2R2B-Myc was 










PP2A activity is required for dephosphorylation of p70S6K and Myc by PPP2R2B 
re-expression 
To confirm that dephosphorylation of p70S6K (T421/424) or Myc on PPP2R2B 
re-expression requires PP2A activity, we depleted the A subunit of PP2A complex by 
siRNA in DLD1-PPP2R2B cells and showed that this manipulation clearly prevented 
the dephosphorylation of Myc and p70S6K by PPP2R2B in PPP2R1A knockdown 
cells compared to siNC cells (Figure 4.14A). These experiments provided evidence to 
demonstrate a functional role of the PPP2R2B-PP2A complex in modulating p70S6K 
and Myc phosphorylation. In addition, we carried out co-immunoprecipitation to 
demonstrate that p70S6K and Myc are direct substrates of PP2A-PPP2R2B. The 
co-IP results showed that p70S6K was detected in PP2A-PPP2R2B 
immunoprecipitates, which indicated that p70S6K physically interact with PPP2R2B 
and direct target of PPP2R2B-associated PP2A complex (Figures 4.14B and 14C). 
However, we were unable to detect the physical interaction between Myc with 
PPP2R2B. Although another PP2A subunit B56α has been previously shown to 
interact and dephosphorylate Myc in HEK293 cells (Arnold and Sears, 2006; Junttila 
et al., 2007), PPP2R2B-PP2A complex may modulate Myc phosphorylation indirectly 
in CRC cells. Taken together, these findings suggested that PP2A activity is required 







Figure 4.14 PP2A activity is required for dephosphorylation of p70S6K and 
Myc by PPP2R2B re-expression 
(A) Immunoblot analysis of DLD1-PPP2R2B cells for Myc, p-Myc (S62), and 
p70S6K, treated PPP2R1A siRNA or a negative control siRNA, with or without Dox 
treatment.  
(B) DLD1-PPP2R2B cells were treated with Dox for 8 h and cell extracts were 
subjected to immunoprecipitation with S6K antibody and interaction of S6K with 
B55ß and PP2A C subunit were studied by immunoblotting of the 
immunoprecipitates. 
(C) DLD1-PPP2R2B cells were treated as (A) and cell lysate were 
immunoprecipitated with Myc-tagged antibody and the interaction of B55ß with S6K 









Downregulation of Myc but not p70S6K inhibit cell growth in CRC 
To evaluated the functional significance of Myc and p70S6K downregulation in CRC,  
siRNA targeting p70S6K or Myc were used to examine the functions in DLD1 and 
HCT116 cells. Cell proliferation were measured by CellTiter-Glo® Luminescent Cell 
Viability Assay Kit after siRNA treatment. The data showed that Myc knockdown 
strongly suppressed DLD1 cell viability, whereas p70S6K knockdown did not yield a 
significant effect in both HCT116 and DLD1 cells(Figure 4.15A). Moreover, 
PPP2R2B re-expression did not induce further growth inhibition when Myc was 
depleted in the cells (Figure 4.15B). Therefore, this data indicate a functional 
contribution of Myc inhibition to the growth inhibitory effect of B55β, which is 
consistent with the established role of Myc in colorectal tumorigenesis (Korinek et al., 











Figure 4.15 Myc knockdown blocks cell viability in CRC 
(A) Growth curve of HCT116 and DLD1 cells treated with Myc, p70S6K siRNA, or 
negative control siRNA for indicated number of days. 
(B) Growth inhibition of DLD1-PPP2R2B cells induced by Myc knockdown, 





















    In this chapter, we have demonstrated that PPP2R2B which encodes for the 
PP2A regulatory B55β subunit, is epigenetically inactivated by DNA 
hypermethylation in the promoter in colorectal cancer. The functional effects of 
re-expression of PPP2R2B in CRC reverses the cancer phenotypes, which include 
senescence, decreased cell proliferation, and xenograft tumor growth inhibition. In 
contrast, PPP2R2B knockdown promotes cell transformation in immortalized 
epithelial cells. Despite current evidence has established that loss of PP2A is required 
for malignant transformation (Chen et al., 2004; Janssens et al., 2005; Zhao et al., 
2003), only a few reports thus far have presented potential mechanisms for the 
inhibition of PP2A activity in spontaneously developing human tumors (Junttila et al., 
2007; Neviani et al., 2005; Sablina et al., 2007). In this regard, low-frequency genetic 
alterations of PP2A subunits have been found in human cancers (Calin et al., 2000; 
Wang et al., 1998), which make it difficult to reconcile PP2A’s role as a bona fide 
tumor suppressor with little evidence showing the profound and widespread 
alterations of PP2A subunits in human cancers. In addition, overexpression of PP2A 
inhibitor proteins, such as CIP2A and SET, were recently reported to promote 
malignant growth through inhibiting PP2A tumor suppressor activity. Considering this 
evidence, it is clear that the identification of PPP2R2B with tumor suppressor 
function is important and expands understanding of the underlying mechanisms how 
PP2A works as tumor suppressor in CRC. In addition to colorectal cancer, PPP2R2B 
may also be downregulated in other cancers such as bladder, brain and esophagus 
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carcinoma, as suggested by Oncomine database. Thus, considering the low frequency 
of PP2A mutations among various subunits (<15%), the epigenetic mechanism 
leading to PP2A inactivation may play a more significant role in the development of 
human cancer like CRC. 
     Due to the substrate diversity of PP2A regulatory subunits, it is not surprising to 
observe numerous oncogenic signaling pathways affected in various tissues or cellular 
contexts. We hypothesize that the loss of PPP2R2B associated specific PP2A complex 
may lead to the disruption of certain oncogenic signaling pathways required for CRC 
cell survival and proliferation. Thus, this study explored the role of PPP2R2B in 
regulating of these oncogenic pathways in CRC. The mTOR downstream effector and 
oncogenic protein Myc were identified as direct or indirect targets of PPP2R2B. 
Among these substrates, Myc was identified as a crucial downstream target of 
PPP2R2B and inactivation of Myc by PP2A-PPP2R2B was consistent with the strong 
growth inhibition effect of PPP2R2B on CRC cells. This is in agreement with a 
crucial role of Myc in CRC tumorigenesis (Sansom et al., 2007). Although PPP2R2B 
has no discernable effect on Wnt pathway in CRC cells, it regulates Myc 
phosphorylation and protein accumulation. Thus its effect on Myc is consistent with 
the strong growth inhibition effect of PPP2R2B on CRC cells that are addicted to Wnt 
pathway for growth advantage. It is well established that Myc is one of substrate 
targets for PP2A (Arnold and Sears, 2006; Junttila et al., 2007; Yeh et al., 2004); 
ectopic expression of SV40 small T or PP2A inhibitor protein CIP2A regulate myc 
stablitiy through association and phosphorylation of Myc. In this study, we show that 
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Myc is not the direct substrate of PPP2R2B-associated PP2A complex, which indicate 
that loss of PPP2R2B may activiate unknown kinase activity, which lead to Myc 
phosphorylation and accumulation in human malignancies. Thus, further investigation 
of the specific substrates targeted by PPP2R2B in PP2A complex may provide an 


























5 Chapter V : PPP2R2B controls PDK1-directed 
Myc signaling and modulates rapamycin 














The phosphatidylinositol 3-kinase (PI3K)-AKT pathway plays a central role in 
cancer development and it is one of the most frequently deregulated signaling 
pathways in human cancers (Cully et al., 2006; Vivanco and Sawyers, 2002). 
Genetic aberrations in this pathway, such as activating mutations of PIK3CA or 
inactivation of PTEN, are identified virtually in all epithelial tumors (Li et al., 1997; 
Samuels et al., 2004). Activation of this pathway in cancer suggests that PI3K, AKT, 
and other components of this pathway may be attractive targets for cancer therapy. 
One of the PP2A regulated cancer signaling pathways is mTOR (Mammalian Target 
Of Rapamycin) pathway which is a key component of PI3K-AKT pathway that 
many cancer cells are coferred with a growth advantage following its constitutive 
activation (Guertin and Sabatini, 2007; Sabatini, 2006).  
In recent years, inhibitors targeting mTOR pathway are under active clinical 
development as anti-cancer therapeutics. Although small molecule mTORC 
inhibitors, such as rapamycin and its analogs have shown promising rationale for its 
use in cancer therapy (Guertin and Sabatini, 2009; Hudes et al., 2007), these 
inhibitors have limited efficacies and the clinical outcomes are often unpredictable. 
Thus, rapamycin resistance has emerged as a major challenge for clinical application. 
The well-documented mechanisms of rapamycin resistance are often linked to its 
negative feedback loops, which partially resulted in hyperactivation of PI3K/AKT 
and MAPK/ERK signaling in rapamycin-treated cells (Carracedo et al., 2008a; 
Carracedo et al., 2008b; Sarbassov et al., 2006). However, the mechanisms 
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underlying the development of rapamycin resistance remain elusive. Therefore, a 
deeper understanding of cancer cells acquired rapamycin resistance and the 
identification of biomarkers that could help to predict therapeutic responses are 
pivotal to the success of the clinical application of mTOR inhibitors (Mao et al., 
2008; Scott et al., 2009; Thomas et al., 2006; Yu et al., 2011).   
In the Chapter four, we described a subunit of the PP2A holoenzyme, 
PPP2R2B, which was epigenetically inactivated in human colorectal cancer. Gain- 
and loss-of-function analyses revealed that PPP2R2B-associated PP2A complex 
works as a tumor suppressor in CRC by negatively inhibiting Myc phosphorylation 
and mTOR downstream effector p70-S6K phosphorylation leading to the 
phosphorylation of S6 ribosomal protein. The connection between PPP2R2B and 
mTOR/S6K/S6 signaling pathway inspired us to investigate the hypothesis that 
PPP2R2B-associated PP2A complex may be implicated in the cellular sensitivity of 
mTOR inhibitor rapamycin in CRC. In this chapter, rapamycin was found to induce 
strong Myc phosphorylation which causes aquired resistance in CRC. Restoration of 
the PPP2R2B-associated PP2A complex inhibits rapamycin-induced Myc 
phosphorylation and enhances the sensitivity of CRC to rapamycin. In contrast to the 
previously described rapamycin-induced AKT phosphorylation, induction of Myc 
phosphorylation by rapamycin in our system is depdent on PDK1 instead of 
PI3K/AKT feedback pathway. Hence, we identified a PPP2R2B-PP2A tumor 
suppressor mechanism controlling PDK1 and Myc phosphorylation and propose that 
a epigenetic defect in this mechanism in cancer might facilitate tumor cells to 
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acquire resistance to mTOR-based cancer therapy.  
 
5.2 Results 
5.2.1 PPP2R2B re-expression sensitizes mTOR inhibitor 
rapamycin 
PPP2R2B re-expression in CRC sensitizes mTOR inhibitor rapamycin in vitro 
The mTOR kinase inhibitor rapamycin has a sporadic anti-cancer activity and its 
effect on mTOR downstream substrate p70S6K is often used as a surrogate marker to 
evaluate rapamycin response (Sawyers, 2008). The plausible connection between 
PPP2R2B and p70S6K signaling leads us to investigate the possibility that PPP2R2B 
expression status may affect the cellular sensitivity to rapamycin. We thus compared 
the effect of rapamycin on cell viability of DLD1-PPP2R2B cells in the presence or 
absence of Dox. DLD1-PPP2R2B cells were treated with 10nM mTOR inhibitor 
rapamycin following 10ng/ml Dox treatment for 7 days. Cell viability was measured 
using CellTiter-Glo™ Luminescent Cell Viability Assay Kit every other day. We 
treated DLD1-vector cells in the same manner as a negative control. The proliferation 
assay showed that rapamycin-induced growth inhibition was much more effective 
when PPP2R2B was re-expressed following Dox treatment in DLD1-PPP2R2B cells, 
but not in the control cells (Figure 5.1A). Moreover, colony formation assay also 
indicated that PPP2R2B re-expression increases the sensitivity of rapamycin 
treatment in CRC cells when we treated with 10nM rapamycin in the absence or 
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presence of Dox in DLD1-vector and DLD1-PPP2R2B cells for 14 days (Figure 
5.1B). In addition, cell cycle analysis by flow cytometry was carried out in an attempt 
to understand the mechanisms involved in the synergy effects of PPP2R2B and 
rapamycin in the suppression of cell growth and cell proliferation. DLD1 inducible 
cells were treated with 10nM rapamycin in the presence or absence of Dox for 48 hr 
for flow cytometer analysis. The FACS results showed that Dox induction of 
PPP2R2B expression resulted in cell cycle G2 arrest, which was further augmented 
with the addition of rapamycin, indicating that PPP2R2B and rapamycin 
synergistically induced cell cycle arrest in G2/M phase (Figure 5.2). In generally, 
these results indicated that the restoration of PPP2R2B increases the sensitivity of 
















Figure 5.1 PPP2R2B re-expression and rapamycin treatment synergistically 
inhibits cell growth and cell proliferation. 
(A) Proliferation of DLD1-vector and DLD1-PPP2R2B cells treated with 10 ng/ml 
Dox or 10 nM rapamycin or both (R+D) for indicated days. Error bar shows the mean 
± SD of triplicates. RLU represents relative light unit. 
(B) Dense foci formation on a monolayer of DLD1-vector or DLD1-PPP2R2B cells 






Figure 5.2 PPP2R2B re-expression and rapamycin treatment synergistically 
induced cell cycle arrest in G2/M phase. 
Cell cycle G2/M arrest in DLD1-vector or DLD1-PPP2R2B cells treated with 
1.0µg/ml Dox or 10nM rapamycin or both for 48 hr. Error bar shows the mean ± SD 















PPP2R2B re-expression in CRC sensitizes cells to rapamycin in vivo 
To verify the in vitro results in vivo, we studied the effects of Dox and rapamycin on 
xenograft tumor growth in nude mice using DLD1-PPP2R2B cells. While single 
treatment with rapamycin or Dox resulted in modest attenuation of the tumor growth; 
the combination gave rise to a strong anti-tumor growth effect in the DLD1-PPP2R2B 
cells as compared to the control cells (Figure 5.3). The results obtained from both in 
vitro and in vivo studies collectively indicated that the PPP2R2B re-expression in 
CRC cells led to improved therapeutic effect of rapamycin. Thus, the data suggested 
that epigenetic loss of PPP2R2B may be a molecular event affecting the sensitivity of 
CRC to mTOR inhibitors. 
 
Figure 5.3 Xenograft tumor growth of DLD1-PPP2R2B cells in nude mice 
Xenograft tumor growth of DLD1-PPP2R2B cells in nude mice treated with Dox at 
100 mg/kg, or rapamycin at 4 mg/kg or both, every other day. Error bars represent ± 
SEM (n = 8 per group). ***p < 0.01(independent t test). 
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5.2.2 Rapamycin induces Myc phosphorylation and protein 
accumulation in CRC cells, which is overridden by PPP2R2B 
re-expression 
Rapamycin induced Myc phosphorylation is blocked by PPP2R2B re-expression  
A feedback mechanism leading to PI3K activation and AKT S473 phosphorylation in 
a mTORC2-depenent manner has been linked to rapamycin resistance in cancer 
(O'Reilly et al., 2006; Sarbassov et al., 2006). Indeed, rapamycin treatment of CRC 
cells resulted in the induction of AKT S473 phosphorylation, but this phosphorylation 
seemed to be unaffected by PPP2R2B re-expression (Figure 5.4A). In contrast, both 
p70S6K and S6 phosphorylation were effectively abolished by rapamycin treatment in 
both vector control and PPP2R2B expressing cells (Figure 5.4A). Thus we excluded 
the possibility that PPP2R2B-induced rapamycin sensitization is associated with AKT 
S473 or p70S6K. On the contrary, and intriguingly, we found that rapamycin 
treatment resulted in a strong induction of Myc phosphorylation and protein 
accumulation. This effect on Myc protein was not due to increased Myc mRNA as 
detected by real-time qPCR (Figure 5.4B) and was nearly completely abolished upon 
PPP2R2B re-expression (Figure 5.4A). To further evaluate the effect of rapamycin in 
Myc phosphorylation in CRC, a time course treatment of rapamycin was performed in 
DLD1 cells. Immunoblotting analysis indicates that the Myc response occurred as 
early as 4 hours, in parallel with the induction of AKT S473 phosphorylation, 




Figure 5.4 Rapamycin Induced Myc Phosphorylation and protein accumulation 
in CRC cells 
(A) DLD1-PPP2R2B or DLD1 vector control cells were treated with 10 nM 
rapamycin in the presence or absence of Dox for 48 hr. The immunoblotting analysis 
shows that rapamycin induces Myc S62 phosphorylation, which is abrogated on 
PPP2R2B expression. 
(B) TaqMan assay of Myc mRNA change in response to rapamycin treatment. Bar 
respresents the mean ± SD of triplicates. 
(C) Immunoblotting analysis of indicated proteins in DLD1 cells treated with 10 nM 









Rapamycin induces Myc phosphorylation through mTORC1 inhibition, but not 
mTORC2 inhibition 
Rapamycin-induced AKT(S473) phosphorylation is mediated by a feedback loop 
through mTORC2- and PIK3CA-dependent manner, which linked to rapamycin 
resistance (Sarbassov et al., 2006). To investigate whether induction of Myc by 
rapamycin is the same pathway as AKT activation, retroviral shRNA vectors targeting 
mTORC1 and mTORC2 components were introduced into DLD1 cells and were 
subsequently harvested for immunoblotting analysis. As shown in figure 5.5, the 
rapamycin-induced Myc phosphorylation and accumulation was indeed the result of 
mTORC1 inhibition, as knockdown of raptor, an essential component of mTORC1, 
but not mTORC2 component rictor, resulted in a similar induction of Myc 
phosphorylation. Given the importance of Myc in CRC tumorigenesis, this 
observation immediately suggests a possible mechanism underlying the 
PPP2R2B-mediated sensitization to rapamycin.   
 
Figure 5.5 Rapamycin induces Myc phosphorylation through mTORC1 
inhibition 
Immunoblotting analysis of Myc in DLD1 cells treated with shRNAs targeting mTOR, 
raptor, or rictor. 
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Lack of PPP2R2B expression correlates with rapamycin resistance and Myc response 
 
To substantiate the association of PPP2R2B expression with Myc response and 
rapamycin sensitivity, we compared the HCT116 cells with DNMTs-deficient 
HCT116 (DKO) cells in which PPP2R2B becomes re-expressed as a result of 
promoter demethylation. As in DLD1 cells, Myc phosphorylation was strongly 
induced by rapamycin in HCT116 cells, whereas in DKO cells, Myc was expressed in 
a low basal level, and did not respond to rapamycin (Figure 5.6A). Notebly, AKT 
Serine 473 phosphorylation was similarly induced by rapamycin in both cell lines, 
regardless of PPP2R2B expression status (Figure 5.6A). Accordingly, DKO cells 
which displayed no Myc response were more sensitive to rapamycin treatment as 
compared to the parental HCT116 cells (Figure 5.6B). Taken together, the effect of 
PPP2R2B on Myc highly correlated with the rapamycin response and support a role 
of PPP2R2B in regulating Myc phosphorylation and thus rapamycin sensitivity. 
Moreover, corresponding to the consistent silencing of PPP2R2B in CRC, all the 
CRC cell lines we have examined exhibited a marked induction of Myc 
phosphorylation upon rapamycin treatment (Figure 5.6C). In agreement with the Myc 
induction, all these CRC cell lines were in general resistant to rapamycin, showing the 
growth inhibition for less than 10% after 5 days treatment with 10 nM rapamycin 
(Figure 5.8B), a concentration that often results in strong growth inhibition in other 
cancer cell lines (Figure 5.8B). This indicated that the lack of PPP2R2B in CRC cells 


































Figure 5.6 Lack of PPP2R2B expression correlates with rapamycin resistance 
and Myc response 
(A) Immunoblot analysis of Myc, AKT and p70S6K in HCT116 and DKO cells 
treated with10 nM rapamycin for the indicated times 
(B) Rapamycin induced growth inhibition in HCT116 and DKO cells. 
(C) Immunoblotting analysis of indicated proteins in CRC cell lines treated with or 
without rapamycin. 
(D) Growth inhibition induced by rapamycin in CRC cell lines assessed by 
CellTiter-Glo Luminescent Cell Viability Assay and normalized to untreated cells. 












PPP2R2B expression determines Myc induction and rapamycin sensitivity 
In contrast to colon cancer, the Oncomine database revealed increased PPP2R2B 
expression in several other human malignancies, including renal, liver, and ovarian 
cancers (Figure 5.7A). Real-time Taqman assay validated the PPP2R2B expression in 
a series of cell lines derived from above tumors, including HepG2 and HepB3 cells 
form hepotoma; 786-O and Caki2 cells from renal carcinoma; OVCAR3, OVCAR5, 
and SK-OV-3 cells from ovarian carcinoma; as well as U2OS cells from 
osteosarcoma, as opposed to the silenced expression of PPP2R2B in CRC lines 
(Figure 5.7B). To check whether the PPP2R2B expression determines Myc induction 
and rapamycin sensitivity, all cancer cells were treated with 10nM rapamycin for 48 
hr and harvested for immunoblotting analysis. As shown in figure 5.8A, rapamycin 
consistently induces the AKT S473 phosphorylation and completely suppresses the 
S6K T389 phosphorylation. Of significant notice, none of these PPP2R2B-expressing 
cancer cell lines showed an induction of Myc phosphorylation in response to 
rapamycin, despite a consistent induction of AKT S473 phosphorylation in all cases 
(Figure5.8A). Moreover, these cell lines were much more sensitive to rapamycin in 
general, as compared to CRC cell lines (Figure 5.8B). The overall results have 
provided evidence to show: 1) the PPP2R2B silence or expression in cancer cells 
correlates with the sensitivity or resistance to rapamycin; 2) This correlation is 





Figure 5.7 PPP2R2B is not downregulated in renal, liver, lymphoma and 
ovarian cancer cells 
 (A) Box-plots showing the differential expression of PPP2R2B mRNA in renal (Boer 
etal., 2001), liver (Chen et al., 2002), lymphoma (Alizadeh et al., 2000), ovarian 
cancer (Hendrix et al., 2006) and corresponding normal tissues obtained from 
ONCOMINE database. The y-axis represents normalized expression and the P-Values 
for correlation are shown below. 
(B) Taqman assay of PPP2R2B mRNA in indicated cancer cell lines and normal 










Figure 5.8 Expression of PPP2R2B in cancer cells correlates with Myc induction 
and rapamycin response. 
 (A) Immunoblot analysis of indicated proteins in non-CRC cell lines that express 
PPP2R2B, treated with or without rapamycin. 
(B) Growth inhibition induced by rapamycin in CRC cell lines and non-CRC cancer 
cell lines as assessed by CellTiter-Glo Luminescent Cell Viability Assay and 
normalized to untreated cells. Cell were treated with 10nM repaying for 5 days. Bar 










5.2.3 Rapamycin-induced Myc phosphorylation is 
PDK1-dependent, but PIK3CA-AKT independent.  
Rapamycin induces Myc phosphorylation through PIK3CA-AKT independent 
manner. 
mTORC2-dependent AKT S473 activation depends on receptor tyrosine kinase 
signaling upon growth factor stimulation (Guertin and Sabatini, 2007; Sekulic et al., 
2000), and PIK3CA (encoding p110α) is required for this process (Jia et al., 2008; 
Knight et al., 2006; Zhao et al., 2006). To investigate the relationship between 
PIK3CA and Myc induction, we cultured DLD1 cells with serum starvation medium 
(DMEM with 0.25% FBS) for 48 hr to eliminate the effect of growth factor in the 
cell culture. The serum starved cells were treated with 10nM rapamycin at different 
time courses and harvested for immunoblotting analysis. The results showed that 
serum starvation abolished rapamycin-induced AKT S473 phosphorylation, which 
was dependent on growth factor stimulation, and had no significant effect on 
rapamycin-induced Myc phosphorylation (Figure 5.9A). these data indicate that 
rapamycin–induced Myc phosphorylation is independent to PIK3CA. To further 
confirm this finding, we used PIK-103, a dual PIK3CA and mTORC1 inhibitor (Fan 
et al., 2006), to treat DLD1 cells and the immunoblotting analysis results showed 
that PIK-103 reduced AKT S473 phosphorylation, but enhanced Myc 
phosphorylation (Figure 5.9B). These findings suggest that rapamycin induces Myc 





Figure 5.9 Rapamycin induces Myc phosphorylation through PIK3CA-AKT 
independent manner. 
(A) Immunoblotting analysis of DLD1 cells for AKT and Myc. DLD1 cells were 
serum starved for 48 hr and followed by treatment with 10 nM rapamycin for the 
indicated time points. 
(B) Immunoblotting analysis of DLD1 cells for AKT and Myc in response to a dual 

























Rapamycin-Induced Myc Phosphorylation Requires PDK1 but not PIK3CA-AKT 
pathway 
To further elucidate the upstream signals leading to rapamycin-induced Myc 
phosphorylation, we knocked down several major components in the PI3K and 
mTOR pathway using siRNAs targeting PIK3CA, PIK3CB, PDK1 and AKT1. 
siRNA transfected cells were treated with 10nM rapamycin for 48 hr and cells were 
harvested for immunoblotting analysis. The western blot results showed that PDK1 
knockdown effectively inhibited rapamycin-induced Myc phosphorylation, while 
knockdown of PIK3CA, PIK3CB, or AKT1 had no such an effect (Figure 5.10A). 
Further experiments with two additional PDK1 siRNAs and a PDK1 shRNA in 
DLD1 and SW480 cells confirmed its effect on Myc phosphorylation (Figure 5.10B 
and 10C); but of notice, PDK1 knockdown had no discernable effect on AKT-S473 
phosphorylation, which however can be clearly abolished by PIK3CA knockdown 
(Figure 5.10A).  
To substantiate this finding, we made use of specific small molecule inhibitor 
of PDK1, BX912 (Feldman et al., 2005) and a specific PIK3CA inhibitor PIK90 (Fan 
et al., 2006; Knight et al., 2006). SW480 cells were treated with BX912 or PIK90 in 
the presence or absence of rapamycin for 48 hr and harvested for immunoblotting 
analysis. Figure 5.10D indicated that BX912 treatment abolished rapamycin-induced 
Myc phosphorylation as consistent with PDK1 knockdown, but had not much effect 
on AKT S473. In contrast, PIK90 was unable to inhibit rapamycin-induced Myc 
phosphorylation; yet it can effectively abolished the AKT S473 phosphorylation 
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(Figure5.10D). Taken together, these results provided concrete evidence to show that 
rapamycin induces a PDK1-dependent Myc phosphorylation, in parallel to 
PIK3CA-sensitive AKT S473 phosphorylation.  
 
 
Figure 5.10 Rapamycin induced Myc phosphorylation requires PDK1 but not 
PIK3CA-AKT pathway. 
(A) Immunoblot analysis of DLD1 cells for Myc, AKT, PI3K, or PDK1. Cells were 
transfected with siRNAs targeting the indicated genes or a negative control siRNA for 
48 hr, followed by 10 nM rapamycin treatment for 24 hr. 
(B) Immunoblot analysis of PDK1, Myc and AKT in DLD1 cells transfected with two 
different PDK1 siRNAs or a negative control siRNA and then treated with 10 nM 
rapamycin for 24 hr. 
(C) Immunoblot analysis of PDK1, Myc, and AKT in SW480 cells infected with a 
retroviral PDK1 shRNA. 
(D) Immunoblot analysis of Myc, AKT, and S6K in DLD1 cells treated with PDK1 
inhibitor BX912 (2.5 mM), or p110a inhibitor PIK90 (5 mM), rapamycin (10 nM) or 





Ectopic expression of PDK1 leads to exogenous and endogenous Myc 
phosphorylation and Myc accumulation 
PDK1 is the master regulator of AGC kinase members, including AKT, p70 
ribosomal S6 kinase (S6K), serum- and glucocorticoid-induced protein kinase (SGK) 
and protein kinase C (PKC) family members, which play crucial roles in regulating 
physiological processes such as metabolism, growth, proliferation and survival (Mora 
et al., 2004). In human cancers, elevation of PIP3 owing to loss of PTEN or gain of 
PIK3CA activity may cause constitutive activation of PDK1. In addition, gene 
amplification or altered phosphorylation can also contribute to excessive PDK1 
activity in human malignancies such as breast and colon cancers (Lin et al., 2005; 
Maurer et al., 2009). To identify the relationship between PDK1 and Myc, we 
investigated whether ectopic expression of PDK1 can lead to Myc phosphorylation. 
Cotransfection of PDK1 and Myc in 293T cells resulted in a huge induction of Myc 
phosphorylation and protein accumulation (Figure 5.11A), and this induction of Myc 
was effectively abolished by PDK1 inhibitor BX912, but not by p110a inhibitor 
PIK90, which efficiently blocks PI3K downstream effector AKT phosphorylation 
(Figure 5.11B). To examine whether ectopic expression PDK1 induces endogenous 
Myc phosphorylation, two immortalized epithethial cell lines MCF-10A and 
HEK-TERV were stably introduced with PDK1. The immunoblotting analysis 
indicated that ectopic PDK1 can also induced endogenous Myc phosphorylation in 
these cells (Figure 5.11C). Collectively, these results demonstrate that PDK1 results 




Figure 5.11 Etopic expression of PDK1 results in Myc phosphorylation 
(A) Immunoblot analysis of Myc in 293T cells transfected with Myc, PDK1, or both. 
(B) Immunoblot analysis of Myc in 293T cells transfected with Myc, PDK1, or both, 
treated with or without PDK1 inhibitor BX912, or PIK3CA inhibitor PIK90. 
(C) Immunoblot analysis of endogenous Myc in MCF10A and HEK-TERV cells 











5.2.4 PPP2R2B binds to and inhibits PDK1 activity  
PPP2R2B binds to PDK1 protein in exogenous and endogenous system 
 
PP2A regulates kinase phosphorylation through binding to and inhibiting the kinase 
activity (Sablina et al., 2007). We next tested the possibility that PPP2R2B may 
directly interact with PDK1 and modulate its activity. This hypothesis was confirmed 
by co-transfection of PPP2R2B and PDK1 plasmids in 293T cells followed by 
co-immunoprecipitation analysis with ectopic PDK1 and PPP2R2B-Myc 
(Figure5.12A). This interaction was further confirmed in DLD1-PPP2R2B cells in 
which Dox-induced PPP2R2B co-immunoprecipitated with endogenous PDK1 
(Figure5.12B). To show the interaction between the endogenous PDK1 and 
PPP2R2B proteins, we took the advantage of HEK-TERV and 
HEK-TERV-PPP2R2B (B55β) shRNA cells and conducted the 
coimmunoprecipitation experiments using PDK1 and B55 antibody, respectively. 
The result shows that the endogenous PDK1 clearly interacted with total B55 and 
this interaction was largely diminished on B55β depletion (Figure5.12C). This result 










Figure 5.12 PPP2R2B interacts with PDK1 
 (A) Coimmunoprecipitation assay in 293T cells transfected with B55β-Myc, 
PDK1-HA, or both. 
(B) Coimmunoprecipitation assays in DLD1-PPP2R2B cells. Cells were treated with 
or without Dox for 24 hr and B55b-Myc or PDK1 were pulled down and subjected 
to immunoblot analysis. 
(C) Coimmunoprecipitation assays in HEKTERV and HEKTERV-shPPP2R2B cells 
using B55 antibody and PDK1 antibody, respectively. The endogenous interaction 











PPP2R2B inhibits PDK1 membrane recruitment, resulting in inhibition of its activity 
It is known that PDK1 needs to be recruited from the cytosol to the plasma 
membrane to activate its downstream targets (Kikani et al., 2005). Both PPP2R2B 
and PDK1 are predominantly located in the cytoplasm (Figure 5.13A and 13B). Thus, 
the cytoplasmic interaction of PDK1 with PPP2R2B may affect its membrane 
recruitment. Indeed, upon Dox treatment of DLD1-PPP2R2B cells, we detected the 
downregulation of both total and phosphorylated PDK1 in plasma membrane (Figure 
5.14A). Moreover, in DLD1-PPP2R2B cells under serum starvation, ectopic 
PDK1-HA was mainly detected in the cytosol, but expressed in both cytosol and cell 
membrane upon serum stimulation, which was abolished when cells were treated 
with Dox to induce PPP2R2B (Figure 5.14B). As a consequence of this inhibitory 
effect on PDK1 membrane localization, we show that p-PKCζ(T410), a known 
PDK1 substrate was downregulated by PPP2R2B re-expression or PDK1 
knockdown, although other examined PDK1 substrates did not seem to be 
significantly regulated by PDK1 in DLD1 cells and were thus not affected by 
PPP2R2B re-expression (Figure 5.14C). The overall result demonstrated that 
B55β-PP2A complex binds and inhibits PDK1 membrane recruitment, resulting in 
the inhibition of its activity toward its downstream substrates. Because Myc is 
accumulated mainly in the nucleus in response to rapamycin (Figure 5.14D), the 
effect of cytoplasmic B55β-PDK1 on Myc is most likely to be indirect and may 
route through PDK1 downstream kinase substrates. Taken together, these results 
demonstrate that PPP2R2B-PP2A complex binds to and inhibits PDK1 membrane 
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recruitment for activation.  
 
 
Figure 5.13 PPP2R2B, PDK1 and Myc cellular localization 
Figure 5.13 PPP2R2B, PDK1 and Myc cellular localization 
(A) DLD1-PPP2R2B cells were treated with Dox for 48h to induce PPP2R2B 
expression and cells were stained with anti-Myc (9E10) and DAPI to detect the 
localization of B55ß-Myc in DLD1 cells. Scale bars=10μm. 











Figure 5.14 PPP2R2B inhibits PDK1 Membrane Localization 
 (A) Immunoblot analysis of the membrane fractions on PDK1 prepared from DLD- 
PPP2R2B cells treated with or without Dox for 48 hr. 
(B) Immunofluorescence for PDK1-HA in DLD1-PPP2R2B with or without serum 
and Dox treatment. Scale bar, 10μm. 
(C) Immunoblot analysis of known PDK1 substrates on PPP2R2B re-expression or 
PDK1 knockdown in DLD1 cells. 
(D) DLD1 cells treated with rapamycin for 48 h and stained with 






5.2.5 Inhibition of PDK1 and Myc, but not PIK3CA and AKT, 
sensitizes therapeutic response of rapamycin  
Knockdown of PDK1 and Myc sensitizes rapamycin response in CRC 
Rapamycin induces Myc phosphorylation through PDK1 pathway but not 
PIK3CA-AKT pathway. To evaluate the underlying mechanisms how the two 
distinct signaling pathways contribute to rapamycin resistance, We knockdown the 
components of PDK1 and PIK3CA pathways using siRNA in HCT116 cells and 
checked the rapamycin sensitivity. Cells were treated with rapamycin for 5 days and 
measured for cell viability. As shown in Figure 5.15A, PDK1 or Myc knockdown 
resulted in markedly increased sensitivity of rapamycin in HCT116 cells, while 
PIK3CA or AKT knockdown did not give rise to a similar effect. To confirm the 
findings in HCT116 cells, a retroviral shRNA targeting PDK1 was introduced into 
SW480 cells and selected for stable cell lines. The stable knockdown cells were 
treated with rapamycin and cell viability was measured. As shown in Figure 5.15B, 
the similar effect of PDK1 ablation on Myc and rapamycin sensitivity was further 
validated in SW480 cells expressing a retroviral PDK1 shRNA. These results 
support a causal relationship between PDK1-Myc induction and rapamycin 
resistance in CRC cells. Moreover, the data argue for a more important role of 
PDK1-Myc signaling, as compared to PIK3CA-AKT signaling, in rapamycin 







Figure 5.15 PDK1 and Myc knockdown sensitizes rapamycin response in CRC 
 (A) HCT116 cells were transfected with siRNAs targeting Myc, PDK1, AKT1, or 
PIK3CA for 48 hr, and then treated with 100 nM rapamycin for 5 days. The graph 
bars show the rapamycin-induced growth inhibition relative to nontreated cells. 
(B) Rapamycin-induced growth inhibition in SW480 cells expressing PDK1 shRNA 














Pharmacological inhibition of PDK1 and rapamycin synergistically induced cell 
cycle arrest in G2/M phase 
Identification of PPP2R2B-regulated PDK1 suggests a practical approach for 
overcoming rapamycin resistance, which may be achieved through pharmacological 
inhibition of PDK1. To examine whether the effect of PDK1 inhibition would be the 
same as PPP2R2B re-expression in colon cancer cells, we compared the changes of 
morphology in SW480 cells treated with PDK1 siRNA and PDK1 inhibitor BX912. 
The microscope images indicated that PDK1 shRNA or BX912, but not PIK90, 
induced a morphological change similar to that seen upon PPP2R2B re-expression in 
SW480 cells. Moreover, BX912, but not PIK90, synergized with rapamycin to induce 
strong G2/M arrest in both DLD1 and SW480 cells (Figure 5.16B), which is again 
remarkably consistent with the synergistic effect of PPP2R2B and rapamycin on 
G2/M cell cycle induction. Thus, pharmacologic inhibition of PDK1, but not PIK3CA, 
has phenocopied the effect of PPP2R2B re-expression, further supporting the genetic 













Figure 5.16 PDK1 inhibition results in similar effects of PPP2R2B re-expression 
in CRC 
(A) Morphologies of SW480 cells under indicated treatments. Scale bars represent 
10μm. 
(B) G2/M phase arrest in SW480 and DLD1 cells induced by rapamycin (10 nM), 
BX912 (2.5 µM), PIK90 (5 µM), single or in combinations, assessed by PI staining 
and FACS analysis. Data are presented as mean ± SD of the percentages of cells 











Pharmacological inhibition of PDK1 can overcome rapamycin resistance 
To further investigate the synergistic effects of inhibition of PDK1 with rapamycin, 
we carried out the cell viability and colony formation assay in both DLD1 and SW480 
cells treated with PDK1 inhibitor in the presence or absence of rapamycin. We 
observed a synergistic loss of cell viability with combined treatment of BX912 and 
rapamycin in cells for a 5-day cell viability assay (Figure5.17C) and a 2-week colony 
formation assay (Figure5.17D). These findings support a model in which the loss of 
PPP2R2B in CRC results in activation of PDK1-dependent Myc phosphorylation in 
response to rapamycin treatment, leading to rapamycin resistance in a PIK3CA-AKT 
independent manner (Figure5.18). Pharmacologic inhibition of PDK1 can overcome 
rapamycin resistance by preventing the Myc phosphorylation, pointing out a potential 













Figure 5.17 Pharmacologic Inhibition of PDK1-Myc Signaling Overcomes 
Rapamycin Resistance 
(A) Cell viability of DLD1 and SW480 cells treated with BX912 (2.5µM), 
rapamycin (10nM), or both for indicated days. 
(B) Dense foci formation for 14 days on a monolayer of DLD1 and SW480 cells 




Figure 5.18 A model indicating a role of B55β-regulated PDK1-Myc pathway in 
modulating rapamycin response. 
Loss of PPP2R2B expression in CRC results in induction of PDK1-dependent Myc 





In this study, we have revealed a novel function of PDK1 toward Myc 
regulation in response to rapamycin, which is correlated with PPP2R2B expression.  
This study has showed that PPP2R2B-associated PP2A complex controls 
PDK1-Myc signaling and modulates rapamycin sensitivity in colorectal cancer. This 
PDK1-Myc signaling is independent of PIK3CA-AKT and may constitute an 
alternative feedback mechanism leading to rapamycin resistance. Although PIK3CA 
and mTORC2-dependent AKT S473 phosphorylation has been suggested to be one 
of crucial feedback mechanisms accounting for the rapamycin resistance in certain 
contexts (O'Reilly et al., 2006; Sarbassov et al., 2006), this pathway in CRC may not 
be as critical as rapamycin resistance that is induced through Myc phosphorylation 
because knockdown of PIK3CA or AKT, does not sensitize cells to rapamycin 
treatment. As such, we propose an AKT-independent signaling pathway comprised of 
PDK1 and Myc phosphorylation contributing to rapamycin resistance in CRC, due to 
loss of PPP2R2B. This notion seems to be consistent with a recent finding that AKT 
is often not required for proliferation of cancer cells with activated PI3K pathway 
(Vasudevan et al., 2009). Thus, the identification of a PDK1-Myc signaling regulated 
by PPP2R2B widens our understanding of cancer cell growth control and rapamycin 
resistance and emphasizes the importance of epigenetic mechanisms in regulating 
oncogenic signaling and therapeutic response. However, although we demonstrate 
that Myc as a downstream target of PDK1, PDK1 may not regulate Myc directly. It 
is possible that PDK1 may route through other downstream kinases to affect Myc 
150 
phosphorylation. The precise feedback mechanism leading to the induction of Myc 
phosphorylation by rapamycin remains elusive and warrants further investigation.  
The dual PI3K-mTOR inhibitors such as PI-103 and NVP-BEZ235 also induce 
PDK1-dependent Myc phosphorylation and Myc protein accumulation in colon 
cancer cells, though these dual inhibitors are able to overcome the activation of AKT 
phosphorylation (Figure 5.9B). These findings point to significant concerns as these 
inhibitors are being tested in clinical trials in various human tumors (Fan et al., 2006; 
Serra et al., 2008). One would expect that this compensatory activation of Myc 
signaling, if validated in the primary tumors, may eventually lead to acquired 
resistance and patient relapse. In agreement with our findings, a recent report also 
suggest that aberrant evelation of Myc by gene amplification represents a potential 
resistance mechanism with respect to current PI3K-targeted therapies in clinical 
trials, which is mediated through a PI3K-independent mechanism (Ilic et al., 2011; 
Liu et al., 2011). Most importantly, considering a potential role of Myc in cancer 
stem cells (Cairo et al., 2008; Kim et al., 2010; Wong et al., 2008), our study 
suggests that caution has to be taken during the development of clinical trials of 
PI3K-mTOR inhibitors in human cancers such as colon, bladder, brain, and 
esophagus tumors in which PPP2R2B might be downregulated. In this aspect, 
expression levels of PPP2R2B or its promoter DNA methylation status might be a 
useful predictive marker to guide the clinical trials of mTOR inhibitors, and Myc 
phosphorylation as a surrogate marker to asses the potential adverse effect of mTOR 
inhibitors in these tumors. To overcome this potential problem, a combinational 
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approach involving PDK1 inhibition might be effective in overcoming Myc 
activation and resistance to mTOR inhibitors, and to produce a more durable cancer 
regression. Of notice, the PDK1-mediated regulation of Myc might not be direct and 
other kinases downstream of PDK1 might be involved in this process. Thus, 
Identification of additional kinases in this pathway will provide additional 
therapeutic targets and inform new therapeutic opportunities.  
Our data support PDK1 as a therapeutic target in CRC, as removal of PDK1 
reduces Myc signaling and alleviate rapamycin resistance. This notion was further 
illustrated using a small molecule PDK1 inhibitor BX912, which is able to abolish 
rapamycin–induced Myc phosphorylation and thus synergizes with rapamycin in 
CRC. Notably, the PDK1 inhibitor as an anti-cancer agent has been shown to be 
effective in vitro and in vivo in cancer (Maurer et al., 2009; Peifer and Alessi, 2008) 
and is currently under clinical development. Therefore, we propose that its 
combination with rapamycin-based mTORC1 inhibitors may become a useful option 
for targeted therapy of CRC.  
Although the rapamycin resistance is well-known to be caused in part by 
feedback loops that activate PI3K-AKT and ERK-MAPK signaling, our studies 
suggest that PDK1-dependent Myc phosphorylation may provide an alternative 
mechanism conferring rapamycin resistance. In fact, rapamycin could not induce 
MAPK phosphorylation in colon cancer cells and rapamycin-induced Myc 
phosphorylation seems play a more effective role than AKT phosphorylation in 
rapamycin resistance, as knockdown of Myc sensitized rapamycin response, which 
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was not observed upon AKT knockdown (Figure 5.16A). As such, we defined a 
novel oncogenic signaling module comprised of PDK1 and myc phosphorylation 
that contributes to rapamycin resistance in colorectal tumors in which PPP2R2B is 
lost.  
In summary, we have demonstrated that Myc induction is independent of AKT 
phosphorylation and thus provides a parallel pathway to mediate rapamycin 
resistance. Rapamycin-induced Myc phosphorylation does not require PIK3CA and 
PIK3CB, which are required for the AKT S-473 phosphorylation by rapamycin. We 
also noticed that in both rapamycin-sensitive and -resistant cell lines AKT is 
consistently upregulated, while Myc induction is only observed in PPP2R2B 
silencing cells that are resistant to rapamycin, but not in rapamycin sensitive and 
PPP2R2B expressing cells. This highlights a distinct role of Myc phosphorylation 
and protein accumulation by PDK1 in mediating rapamycin sensitivity. Thus, this 
alternative feedback mechanism present as promising therapeutic targets for 































In this thesis, by using integrative genomic and epigenomic analysis we 
identified and characterized 203 CMS genes with clinical relevance and potential 
tumor suppressor functions in colorectal cancer. Among these CMS genes, PPP2R2B, 
one of the regulatory B subunit of PP2A, was found to be epigenetically inactivated 
by DNA methylation in CRC. Loss of PPP2R2B causes inactivation of PP2A complex 
and promotes PDK1-Myc signaling, which is required for CRC cell survival and 
proliferation. In agreement with this, gain-of-function analysis of PPP2R2B revealed 
its inhibition of PDK1-Myc axis as a potential tumor suppressor mechanism. 
Moreover, remarkable loss of PPP2R2B-associated PP2A function in CRC conferred 
a strong activation of oncogenic Myc phosphorylation in response to mTORC1 
inhibitor rapamycin, leading to rapamycin resistance. Taken together, these findings 
suggest that aberrant activation of PDK1-Myc is a potential mechanism by which 
tumor cells develop resistance to mTOR inhibition, and thus combination therapies 
targeting both mTOR and PDK1 may be necessary to circumvent resistance to 
PI3K/mTOR-targeted therapy.  
6.1 Meta-analysis of genomic and epigenomic data reveals 
CMS gene set in colon cancer 
Aberrant epigenetic silencing is a prevalent mechanism that could lead to 
inactivation of tumor suppressors in human malignancy (Chan et al., 2008; Jiang et 
al., 2008). One of the predominant modes of epigenetic alterations in cancer is gene 
silencing via DNA methylation of CpG islands in promoter region(Esteller et al., 
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2001; Jones and Baylin, 2007). Increasing evidences have shown that DNA 
hypermethylation results in abnormal silencing of a number of tumor suppressors in 
many solid tumors (Esteller, 2008). Genome-wide identification of DNA methylation 
silencing genes and subsequent functional characterization of the tumor suppressor 
genes in several types of cancers have been performed in previous reports (Schuebel 
et al., 2007; Suzuki et al., 2002; Suzuki et al., 2004). However, the full spectrum of 
tumor suppressor genes silenced by DNA methylation in CRC is not well 
documented.   
In chapter III, by adopting combination analysis of transcriptomic profiling 
and ChIP-seq mapping, we have identified clinically relevant tumor suppressor 
genes that silenced by DNA hypermethylation in CRC. Many of the CMS genes 
were revealed to have functions relevant to tumor biology, cell proliferation, and 
metastasis. Functional studies indicate that some of these genes work as tumor 
suppressors, leading to growth inhibition in cancer cells. Discovery of tumor 
suppressor genes and their related oncogenic signaling pathways that are clinically 
relevant and functionally important is critical for the development of novel 
therapeutics. This study provided a comprehensive approach to identify and 
characterize the silenced tumor suppressor genes in CRC, which has enhanced our 
understanding of the process of tumorigenesis. Previous studies have shown that 
tumor suppressor genes are frequently silenced epigenetically in colon cancer cell 
lines and primary tumors (Suzuki et al., 2002). In agreement with this, a large 
number of CMS genes were uncovered in this study. In addition, many of these 
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genes were previously reported as putative tumor suppressor genes in colorectal 
cancer, such as SOX17 and SFRP1. Thus, this study has significantly uncovered a 
wide array of novel silenced genes that potentially act as tumor suppressors in colon 
cancer.  
6.2 PPP2R2B-associated PP2A complex functions as a 
tumor suppressor 
Aberrant DNA methylation-mediated silencing of tumor suppressor genes often 
resulted in the dysregulation of oncogenic pathways and thus plays as an important 
mechanism in tumorigenesis and resistance to anticancer therapy (Baylin, 2011). 
Increasing evidences have validated that epigenetic alterations collaborate with 
genetic changes to disrupt the core pathways in cancer (2011; Wood et al., 2007; Yi et 
al., 2011). However, most of these studies only focus on the identification of 
molecular abnormalities that influence clinical outcome, the relationship between 
epigenetic alteration and therapeutic resistance is under studied.  
In chapter IV, a specific PP2A regulatory B subunit which encoded B55β was 
identified to be epigenetically inactivated in both CRC cell lines and patient-derived 
CRC samples. Gain- and loss-of-function analyses reveal that PPP2R2B forms an 
active PP2A complex, which works as a tumor suppressor in CRC. Therefore, one of 
the important contributions of this study is the discovery of a potential mechanism 
conferring the inactivation of PP2A tumor suppressors in colon and other human 
cancers. The low frequency of genetic alterations in PP2A subunits is consistent with 
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the previous studies, which indicated that tumor suppressors are mainly inactivated by 
epigenetic changes, such as DNA methylation, rather than genetic mutations (Baylin 
and Ohm, 2006; Schuebel et al., 2007). Our study indicates that the loss of PPP2R2B 
occurs in >90% of colorectal tumor samples was mediated by epigenetic events, 
implying that DNA hypermethylation might be more prevalent mechanism leading to 
loss of PP2A tumor suppressor function in colon cancer.  
Re-expression of PPP2R2B could reverse the cancer phenotypes through 
restoration of its associated-PP2A complex tumor suppressor activity. However, the 
underlying mechanism in which PP2A works as tumor suppressor in CRC is largely 
unknown. Given the substrate diversity and specificity of PP2A regulatory subunits, 
we screened a panel of key components of core oncogenic pathways in CRC and 
revealed that the loss of PPP2R2B associated specific PP2A complex mainly results 
in deregulation of Myc and p70S6K. Genetic disruption of Myc and p70S6K 
indicated that Myc appears to be a crucial downstream target of PPP2R2B-associated 
PP2A and inactivation of Myc by PP2A-PPP2R2B is consistent with the strong 
growth inhibition effect of PPP2R2B on CRC cells. Although a distinct PP2A subunit 
B56α has been shown to associate with Myc and regulates its stability (Arnold and 
Sears, 2006; Junttila et al., 2007; Yeh et al., 2004), we show that PPP2R2B-associated 
PP2A complex indirectly regulate Myc phosphorylation and protein accumulation. 
Thus, the loss of PPP2R2B provides an additional mechanism leading to deregulation 
of Myc in CRC. 
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6.3 Rapamycin-induced Myc phosphorylation as a 
rapamycin resistance mechanism 
The PI3K/AKT signaling impacts on cancer cell growth, survival, and 
metabolism. mTOR is the key downstream component of this pathway, which is 
hyperactivated in many types of cancer (Sabatini, 2006). Misregulated mTOR 
activity is a common feature of most cancers (Alessi et al., 2009); therefore, the 
involvement of mTOR in tumorigenesis has been extensively investigated during the 
past years. Several mTOR inhibitors, such as rapamycin and its analogs, have been 
studied in clinical trial, including renal cell carcinoma, lymphoma, and breast cancer 
(Chan et al., 2005; Hudes et al., 2007; Witzig et al., 2005). However, the clinical 
trials evaluating the mTORC1 inhibitor rapamycin as anticancer agent have met with 
limited success and like most of the targeted therapies are inevitably followed by 
acquired drug resistance (Guertin and Sabatini, 2009). This limited success can be 
explained by the negative feedback loops that resulted in the hyperactivation of 
PI3K/AKT or ERK-MAPK signaling pathways, while additional mechanisms 
contributing to the resistance to mTOR inhibitors may also exist and remain to be 
identified. Considering this, it is imperative to identify the drug resistance 
mechanism and discover the relevant biomarkers that can be used to predict the 
response of human cancers to mTOR inhibitors in order to optimize their utility and 
improve clinical outcomes.    
In chapter V, we found that rapamycin treatment not only induced AKT 
activation, but also led to a strong Myc phosphorylation in colorectal cancers cells. 
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This rapamycin-induced Myc phosphorylation in colon cancer cells is not routed 
through PI3K, but is dependent on PDK1, a master kinase often linked to AKT 
activation. Intriguingly, PDK1 inhibition by either gene knockdown or small 
molecule kinase inhibitor does not affect AKT phosphorylation in colon cancer cells, 
but can markedly abolish Myc phosphorylation, leading to enhanced sensitivity to 
rapamycin in CRC. This suggests that mTORC1 inhibition by rapamycin may trigger 
a separate compensatory mechanism involving PDK1-Myc signaling to attenuate 
rapamycin response. Interestingly, several recent studies have reported similar 
mechanisms of resistance to PI3K-targeted therapy. In one study, tumor induced by 
Myc activation was shown to be highly resistant to BEZ235, a dual PI3K and 
mTORC1/2 inhibitor, compared to PTEN-deficient-induced tumor (Carver et al., 
2011). Likewise, Myc elevation in PI3K-driven mammary tumors represents a 
potential mechanism of resistance to PI3K inhibition (Ilic et al., 2011; Liu et al., 
2011). These studies, along with our present study, strongly suggest that aberrant 
activation of Myc may contribute to acquired resistance in PI3K/mTOR-targeted 
therapy. Although PI3K-dependent AKT phosphorylation has been suggested to be a 
crucial mechanism accounting for the rapamycin resistance in other contexts 
(O'Reilly et al., 2006; Sarbassov et al., 2006), this pathway does not seem to be 
crucial in colon cancer as we found that knockdown of PIK3CA and AKT did not 
significantly sensitize rapamycin-induced growth inhibition. Furthermore, this study 
indicated that the rapamycin-induced Myc phosphorylation in colon cancer appears 
to be a result of the epigenetically loss of expression of PPP2R2B and inactivation of 
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its associated PP2A complex. In colon cancer cells with restored expression of 
PP2A-PPP2R2B or in human cancer cells that do not acquire silencing of  
PP2A-PPP2R2B, rapamycin does not seem to induce Myc phosphorylation and 
these cells were found to be more sensitive to rapamycin. Moreover, this study also 
demonstrated that PPP2R2B-assocated PP2A complex is physically interacting with 
PDK1 and functionally mitigates PDK1-directed Myc phosphorylation. Given the 
high frequency of PPP2R2B silencing (>90%) in CRC, we proposed a model for 
rapamycin resistance in CRC. As shown in Figure 6, rapamaycin induces 
PDK1-dependent Myc phosphorylation, which is negatively regulated by 
PPP2R2B-PP2A complex; while epigenetic inactivation of PPP2R2B results in 
activation of PDK1-Myc signaling upon rapamycin treatment, leading to rapamycin 
resistance. Taken together, these findings identified a crucial role of PP2A-PPP2R2B 
in determining the activity of PDK1-directed Myc signaling response to rapamycin 




Figure 6.1 The role of PP2A-B55β-regulated PDK1-Myc pathway in modulating 
rapamycin response. 
(A) The epigenetic inactivation of PPP2R2B (encoding B55β) by promoter DNA 
hypermethylation in colorectal cancer (CRC) disrupts the PP2A-B55β function 
towards inhibition of PDK1-Myc signaling. (B) Rapamaycin induces 
PDK1-dependent Myc phosphorylation in CRC due to loss of PP2A-B55β, which is 
parallel to PIK3CA/mTORC2-dependent AKT S473 phosphorylation, attenuating 


















6.4 Potenital clinical aplications of this study  
This thesis has revealed several implications for clinical application of 
rapamycin derivatives in human cancer therapy. Firstly, PPP2R2B may be used as a 
predictive biomarker for clinical outcome of mTOR inhibitors in cancer therapy. 
Several rapamycin analogs are currently under the clinical development. 
Unfortunately, clinical updates indicate that rapamycin shows promising results only 
towards a few types of cancers, particularly B-cell lymphoma, endometrial cancer, 
and renal cell carcinoma (Easton and Houghton, 2006; Faivre et al., 2006; Granville et 
al., 2006). Overall, the therapeutic response to rapamycin is highly variable, 
indicating the strong need for biomarkers that are capable of accurately predicting the 
therapeutic effect of rapamycin. As we discussed earlier, the silencing of PPP2R2B by 
DNA methylation occurs in more than 90% of colon primary tumor and this 
epigenetic event impacts the sensitivity of cancer cells to mTOR inhibitors. In this 
study, a strong correlation of the expression of PPP2R2B with the response of 
rapamycin has been revealed. Thus, this finding may have important implications for 
clinical trials of rapamycin derivatives in human cancer.  As such PPP2R2B could 
serve as one of the predictive markers for prognosis of CRC patients as well as for 
patient selection in the clinical trials.    
Secondly, Myc phosphorylation can be used as a surrogate marker to evaluate 
the drug response of rapamycin. In this study, we showed that rapamycin treatment 
resulted in the induction of AKT S473 phosphorylation through a well-known 
feedback mechanism in both sensitive and resistant cancer cells. In contrast, the 
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rapamycin-induced Myc phosphorylation only occurs in resistant cell lines which lack 
of PPP2R2B expression compared to the sensitive cancer cells. Thus, these findings 
suggest that Myc phosphorylation induced by rapamycin may serves as prognostic 
biomarker for mTOR inhibitors in the clinical outcome.  
Finally, this study has highlighted that PDK1 could become a therapeutic target 
in cancer therapy. An additional therapeutic application of this study is the 
identification of a new strategy to overcome resistance to mTOR-targeted therapy in 
CRC. Our data show that ectopic expression of PDK1 promotes Myc phoshorylation 
and protein accumulation; conversely, pharmacological or genetic removal of PDK1 
reduces Myc signaling and alleviates rapamycin resistance. This notion was further 
illustrated using a small molecule PDK1 inhibitor BX912, which is able to abolish 
rapamycin–induced Myc phosphorylation and thus synergizes with rapamycin in CRC. 
In conjunction with these findings, it was reported that genetic ablation of PDK1 in 
human colorectal cancer resulted in markedly reduced proliferation and metastasis 
(Ericson et al., 2010). In addition, the PDK1 inhibitor has been shown to be an 
effective anti-cancer agent in vitro and in vivo (Maurer et al., 2009; Peifer and Alessi, 
2008) and is currently under clinical development. To overcome the resistance of 
mTOR inhibitors in targeted therapy, a combination approach involving PDK1 
inhibition might be appropriate to overcome Myc activation and resistance to mTOR 
inhibitors, and to produce a more durable cancer regression. Therefore, we propose 
that its combination with rapamycin-based mTORC1 inhibitors could be a better 
option for targeted therapy of CRC. Taken together, this study provides an illustration 
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of epigenetic control of important oncogenic signaling pathways and identifies a 
molecular determinant and a potential biomarker of rapamycin sensitivity.  
6.5 Future directions 
This study provides a genome-wide mapping approach to discover 
epigenetically silencing genes by DNA methylation. The subsequent functional 
studies have helped us to identify a panel of putative tumor suppressor genes in CRC. 
However, the underlying mechanism(s) of how these CMS genes work as tumor 
suppressors remains elusive. Although identification and characterization of these 
CMS genes could provide new insights into cancer development, detailed molecular 
mechanisms of these CMS genes need to be further investigated. For example, 
although the differentiation transcription factor HAND1 was identified as a tumor 
suppressor gene in this study and other reports (Martinez Hoyos et al., 2009; Tellez 
et al., 2009), the mechanism is still unknown. Gain-of-function analysis of HAND1 
in inducible cell systems would provide detailed information of the tumor suppressor 
role of HAND1 in CRC. For instance, the gene expression data could be useful for 
identification of HAND1 transcriptional targets and its associated regulatory network. 
On top of that, some of CMS genes encode protein phosphatases, which regulate a 
variety of kinases involved in oncogenic pathways. Epigenetically loss of these 
protein phosphatases may play an important role in the deregulation of oncogenic 
phosphorylation cascades and result in tumorigenesis. Therefore, functional 
investigation of these phosphatases and identification of the substrates or kinases of 
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these phosphatases, would provide new therapeutic targets in cancer treatment. 
In this study, we have revealed aberrant activation of PDK1-Myc signaling in 
colorectal cancer (CRC) and its association with the loss of PP2A-B55β phosphatase 
complex. Although co-immunoprocipitation results show that PDK1 indirectly 
promotes Myc accumulation, the precise mechanism how PDK1 regulates Myc is 
unclear. To understand the mechanisms, PDK1-transformed cell system would be set 
up and used as a model system for screening of the downstream mediators of PDK1 
for Myc regulation. By using this model system, new compounds that could more 
specifically target PDK1 would be developed.  
Clinically, this study reveals a potential resistance mechanism with respect to 
current mTOR-targeted therapies in clinical trials. The positive regulation of PDK1 
toward Myc signaling pathway determines the response of rapamycin in cancer cells. 
Thus, it would be worth to examine the value of PPP2R2B as a predictive biomarker 
for rapamycin treatment in the clinical trial studies. Therefore, preclinical trials 
based on xenograft animal studies should be carried out to check the anti-tumor 
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